Stephan Windecker

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8451476/stephan-windecker-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

753	83,953 citations	114	282
papers		h-index	g-index
829 ext. papers	102,533 ext. citations	7.2 avg, IF	7.35 L-index

#	Paper	IF	Citations
753	Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy 2022 , 1, 100004		1
752	Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial <i>American Heart Journal</i> , 2022 , 247, 33-33	4.9	1
751	Right Ventricular-Pulmonary Arterial Coupling and Afterload Reserve in Patients Undergoing Transcatheter Tricuspid Valve Repair <i>Journal of the American College of Cardiology</i> , 2022 , 79, 448-461	15.1	0
750	Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention <i>Journal of the American College of Cardiology</i> , 2022 , 79, 417-427	15.1	2
749	Frequency and Outcomes of Periprocedural MI in Patients With Chronic Coronary Syndromes Undergoing PCI <i>Journal of the American College of Cardiology</i> , 2022 , 79, 513-526	15.1	1
748	Self-reported non-adherence to P2Y12 inhibitors in patients undergoing percutaneous coronary intervention: Application of the medication non-adherence academic research consortium classification <i>PLoS ONE</i> , 2022 , 17, e0263180	3.7	
747	Complex vs. non-complex percutaneous coronary intervention with newer-generation drug-eluting stents: an analysis from the randomized BIOFLOW trials <i>Clinical Research in Cardiology</i> , 2022 , 1	6.1	1
746	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial <i>Journal of the American Heart Association</i> , 2022 , e024291	6	0
745	Early Clinical Experience With the TRICENTO Bicaval Valved Stent for Treatment of Symptomatic Severe Tricuspid Regurgitation: A Multicenter Registry <i>Circulation: Cardiovascular Interventions</i> , 2022 , CIRCINTERVENTIONS121011302	6	O
744	Functional Status After Transcatheter and Surgical Aortic Valve Replacement: 2-Year Analysis From the SURTAVI Trial <i>JACC: Cardiovascular Interventions</i> , 2022 , 15, 728-738	5	0
743	Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus 2022 , 1, 100033		
742	Diagnostic performance of quantitative coronary artery disease assessment using computed tomography in patients with aortic stenosis undergoing transcatheter aortic-valve implantation <i>BMC Cardiovascular Disorders</i> , 2022 , 22, 178	2.3	1
741	Response by Lakireddy et al to Letters Regarding Article, "Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial" <i>Circulation</i> , 2022 , 145, e850-e851	16.7	2
740	Long-term outcomes of new-onset conduction abnormalities following transcatheter aortic valve implantation <i>Archives of Cardiovascular Diseases</i> , 2022 , 115, 214-224	2.7	0
739	Timing of Stent Thrombosis After 1-Month Discontinuation of Dual Antiplatelet Therapy <i>Journal of the American College of Cardiology</i> , 2022 , 79, 1963-1965	15.1	
738	Electrosurgical Laceration and Stabilization of MitraClip Followed by Valve Implantation for Iatrogenic Mitral Stenosis <i>JACC: Cardiovascular Interventions</i> , 2021 , 15, 110-110	5	0
737	Outcomes Stratified by Adapted Inclusion Criteria After Mitral Edge-to-Edge Repair. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 2408-2421	15.1	2

(2021-2021)

736	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis. <i>Cardiovascular Research</i> , 2021 ,	9.9	3
735	Prediction of radial crossover in acute coronary syndromes: derivation and validation of the MATRIX score. <i>EuroIntervention</i> , 2021 ,	3.1	5
734	Amplatzer left atrial appendage closure: Single versus combined procedures. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 97, E973-E981	2.7	2
733	Sinus of Valsalva Dimension and Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation: SOV dilatation in TAVI patients. <i>American Heart Journal</i> , 2021 ,	4.9	2
732	Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 2060-2072	15.1	2
731	Differential Effects of Newer-Generation Ultrathin-Strut Versus Thicker-Strut Drug-Eluting Stents in Chronic and Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 2461-2473	5	1
730	Outcomes of valve-in-valve transcatheter aortic valve implantation with and without bioprosthetic valve fracture. <i>EuroIntervention</i> , 2021 , 17, 848-855	3.1	3
729	Valve-in-Valve Transcatheter Aortic Valve Replacement for the Treatment of Paravalvular Leak Due to Ring Dehiscence. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 2746-2746	5	O
728	Effect of Timing of Staged Percutaneous Coronary Intervention on Clinical Outcomes in Patients With Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2021 , 10, e023129	6	
727	Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition. <i>EuroIntervention</i> , 2021 , 17, e898-e909	3.1	11
726	Retrograde Retrieval of a Novel Large Mitral Clip After Embolization Into the Left Ventricle. <i>JACC:</i> Case Reports, 2021 , 3, 1561-1568	1.2	0
725	Drug-Eluting or Bare-Metal Stents for Left Anterior Descending or Left Main Coronary Artery Revascularization. <i>Journal of the American Heart Association</i> , 2021 , 10, e018828	6	1
724	Impact of Center Volume on Outcomes in Myocardial Infarction Complicated by Cardiogenic Shock: A CULPRIT-SHOCK Substudy. <i>Journal of the American Heart Association</i> , 2021 , 10, e021150	6	
723	Cysteine-Rich Angiogenic Inducer 61 Improves Prognostic Accuracy of GRACE (Global Registry of Acute Coronary Events) 2.0 Risk Score in Patients With Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2021 , 10, e020488	6	1
722	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. <i>Circulation</i> , 2021 , 144, 1323-1343	16.7	9
721	Predictors of Prosthetic Valve Regurgitation After Transcatheter Aortic Valve Implantation With ACURATE neo in the SCOPE I Trial. <i>JACC: Cardiovascular Imaging</i> , 2021 , 15, 367-367	8.4	O
720	Multimodality Imaging for Evaluation of Bicaval Valved Stent Implantation in Severe Tricuspid Regurgitation. <i>JACC: Case Reports</i> , 2021 , 3, 1512-1518	1.2	
719	Association between self-reported motivation to quit smoking with effectiveness of smoking cessation intervention among patients hospitalized for acute coronary syndromes in Switzerland <i>Preventive Medicine Reports</i> , 2021 , 24, 101583	2.6	

718	Clinical impact of mitral calcium volume in patients undergoing transcatheter aortic valve implantation. <i>Journal of Cardiovascular Computed Tomography</i> , 2021 , 15, 356-365	2.8	6
717	Relationship between arterial remodelling and serial changes in coronary atherosclerosis by intravascular ultrasound: an analysis of the IBIS-4 study. <i>European Heart Journal Cardiovascular Imaging</i> , 2021 , 22, 1054-1062	4.1	
716	Residual inflammatory risk at 12 months after acute coronary syndromes is frequent and associated with combined adverse events. <i>Atherosclerosis</i> , 2021 , 320, 31-37	3.1	О
715	Single antiplatelet therapy with use of prasugrel in patients undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 98, E213-E221	2.7	O
714	Primary Results of the EVOLVE Short DAPT Study: Evaluation of 3-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients Treated With a Bioabsorbable Polymer-Coated Everolimus-Eluting Stent. <i>Circulation: Cardiovascular Interventions</i> , 2021 , 14, e010144	6	15
713	Five-year clinical outcomes of zotarolimus-eluting stents in coronary total occlusions. <i>EuroIntervention</i> , 2021 , 16, 1326-1332	3.1	
712	Impact of effective regurgitant orifice area on outcome of secondary mitral regurgitation transcatheter repair. <i>Clinical Research in Cardiology</i> , 2021 , 110, 732-739	6.1	0
711	Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 639-648	5	11
710	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. European Heart Journal, 2021,	9.5	29
709	The Edwards PASCAL Transcatheter Valve Repair System 2021 , 147-152		
708	Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. <i>Circulation</i> , 2021 , 143, 1215-1223	16.7	1
707	One-Year Outcomes of a Randomized Trial Comparing a Self-Expanding With a Balloon-Expandable Transcatheter Aortic Valve. <i>Circulation</i> , 2021 , 143, 1267-1269	16.7	1
706	Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond. European Heart Journal - Cardiovascular Pharmacotherapy, 2021 , 7, 547-556	6.4	1
7 ⁰ 5	Incidence, predictors, and outcomes associated with acute kidney injury in patients undergoing transcatheter aortic valve replacement: from the BRAVO-3 randomized trial. <i>Clinical Research in Cardiology</i> , 2021 , 110, 649-657	6.1	2
704	Quantitative Flow Ratio to Predict Nontarget Vessel-Related Events at 5 Years in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Angiography-Guided Revascularization. Journal of the American Heart Association, 2021, 10, e019052	6	2
703	Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation: The ARC-High Bleeding Risk Trade-off Model. <i>JAMA Cardiology</i> , 2021 , 6, 410-419	16.2	13
702	Staging cardiac damage associated with aortic stenosis in patients undergoing transcatheter aortic valve implantation. <i>IJC Heart and Vasculature</i> , 2021 , 33, 100768	2.4	2
701	Heart valve sizing and clinical outcomes in patients undergoing transcatheter aortic valve implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 98, E768-E779	2.7	О

(2021-2021)

700	Design and Rationale of the Swiss-Apero Randomized Clinical Trial: Comparison of Amplatzer Amulet vs Watchman Device in Patients Undergoing Left Atrial Appendage Closure. <i>Journal of Cardiovascular Translational Research</i> , 2021 , 14, 930-940	3.3	4	
699	Improving 1-year mortality prediction in ACS patients using machine learning. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 855-865	4.3	2	
698	Efficacy and safety of ethanol infusion into the vein of Marshall for mitral isthmus ablation. <i>Journal of Cardiovascular Electrophysiology</i> , 2021 , 32, 1610-1619	2.7	1	
697	ST-Segment Elevation Myocardial Infarction Following Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2021 , 77, 2187-2199	15.1	9	
696	External validation of the GRACE risk score 2.0 in the contemporary all-comers GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 98, E513-E522	2.7	O	
695	Validation of the 2019 Expert Consensus Algorithm for the Management of Conduction Disturbances After TAVR. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 981-991	5	3	
694	Bioprosthetic valve fracture: Predictors of outcome and follow-up. Results from a multicenter study. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 98, 756-764	2.7	O	
693	Age-Related Outcomes After Transcatheter Aortic Valve Replacement: Insights From the SwissTAVI Registry. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 952-960	5	4	
692	Biodegradable polymer sirolimus-eluting stents vs durable polymer everolimus-eluting stents in patients undergoing percutaneous coronary intervention: A meta-analysis of individual patient data from 5 randomized trials. <i>American Heart Journal</i> , 2021 , 235, 140-148	4.9	5	
691	Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial. <i>Circulation</i> , 2021 , 143, 2143-2154	16.7	3	
690	Hemolysis After Transcatheter Mitral Valve Implantation Resolved by Valve Retensioning. <i>JACC:</i> Case Reports, 2021 , 3, 864-870	1.2	О	
689	P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. <i>BMJ, The</i> , 2021 , 373, n1332	5.9	54	
688	Refined staging classification of cardiac damage associated with aortic stenosis and outcomes after transcatheter aortic valve implantation. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 , 7, 532-541	4.6	1	
687	Impact of Coronary Calcification on Clinical Outcomes After Implantation of Newer-Generation Drug-Eluting Stents. <i>Journal of the American Heart Association</i> , 2021 , 10, e019815	6	2	
686	Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. <i>Journal of the American Heart Association</i> , 2021 , 10, e021965	6	9	
685	N icagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMINa post hoc analysis of the randomized GLOBAL LEADERS trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 756-773	4.3	O	
684	Surgical versus transcatheter repair for secondary mitral regurgitation: A propensity score-matched cohorts comparison. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021 ,	1.5	4	
683	2-Year Outcomes for Transcatheter Repair in Patients With Mitral Regurgitation From the CLASP Study. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 1538-1548	5	6	

682	Effect of Paroxetine-Mediated G-Protein Receptor Kinase 2 Inhibition vs Placebo in Patients With Anterior Myocardial Infarction: A Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 1171-1176	16.2	O
681	Discordance in the diagnostic assessment of vulnerable plaques between radiofrequency intravascular ultrasound versus optical coherence tomography among patients with acute myocardial infarction: insights from the IBIS-4 study. <i>International Journal of Cardiovascular Imaging</i>	2.5	1
68o	Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale: The FABOLUS	3.3	5
679	FASTER Trial. Journal of Cardiovascular Translational Research, 2021, 14, 110-119 Prognostic value of total testosterone levels in patients with acute coronary syndromes. European Journal of Preventive Cardiology, 2021, 28, 235-242	3.9	1
678	Evolution of Basic Activities of Daily Living Function in Older Patients One Year After Transcatheter Aortic Valve Implantation. <i>Journal of the American Geriatrics Society</i> , 2021 , 69, 500-505	5.6	O
677	Impact of individual stroke risk on outcome after Amplatzer left atrial appendage closure in patients with atrial fibrillation. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 97, E1002-E1010	2.7	
676	Transcatheter Mitral Valve Replacement After Surgical Repair or Replacement: Comprehensive Midterm Evaluation of Valve-in-Valve and Valve-in-Ring Implantation From the VIVID Registry. <i>Circulation</i> , 2021 , 143, 104-116	16.7	27
675	Meta-Analysis of Bioprosthetic Valve Thrombosis After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2021 , 138, 92-99	3	10
674	Clinical Outcomes According to ECG Presentations in Infarct-Related Cardiogenic Shock in the Culprit Lesion Only PCI vs Multivessel PCI in Cardiogenic Shock Trial. <i>Chest</i> , 2021 , 159, 1415-1425	5.3	1
673	Synergistic Effect of 2 Transcatheter Tricuspid Valve Treatment Modalities. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, e5-e7	5	
672	Usefulness of updated logistic clinical SYNTAX score based on MI-SYNTAX score in patients with ST-elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 97, E919-E92	8 ^{2.7}	3
671	Discharge Location and Outcomes After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2021 , 140, 95-102	3	1
670	Regional variation in patients and outcomes in the GLOBAL LEADERS trial. <i>International Journal of Cardiology</i> , 2021 , 324, 30-37	3.2	1
669	Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized	6.4	14
668	Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS). <i>American Journal of Cardiology</i> , 2021 , 138, 1-10	3	2
667	Deferred versus Expedited Aortic Valve Replacement in Patients with Symptomatic Severe Aortic Stenosis During the SARS-CoV-2 Pandemic (AS DEFER): A Research Letter. <i>Global Heart</i> , 2021 , 16, 32	2.9	O
666	Patient-tailored antithrombotic therapy following percutaneous coronary intervention. <i>European Heart Journal</i> , 2021 , 42, 1038-1046	9.5	9
665	Five-year outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with acute coronary syndrome: A subgroup analysis of the BIOSCIENCE trial. <i>Cardiovascular Revascularization Medicine</i> , 2021 ,	1.6	1

(2021-2021)

664	True-severe stenosis in paradoxical low-flow low-gradient aortic stenosis: outcomes after transcatheter aortic valve replacement. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 , 7, 366-377	4.6	0
663	Prognostic value of inflammatory biomarkers and GRACE score for cardiac death and acute kidney injury after acute coronary syndromes. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 445	5- 4 132	1
662	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 444-456	5	3
661	Predicting 2-year all-cause mortality after contemporary PCI: Updating the logistic clinical SYNTAX score. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 98, 1287-1297	2.7	2
660	Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 375-388	15.1	19
659	Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e006581	5.8	6
658	Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 361-373	5	10
657	Performing elective cardiac invasive procedures during the COVID-19 outbreak: a position statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>EuroIntervention</i> , 2021 , 16, 1177-1186	3.1	6
656	Transcatheter Tricuspid Valve Intervention in Patients With Right Ventricular Dysfunction or Pulmonary Hypertension: Insights From the TriValve Registry. <i>Circulation: Cardiovascular Interventions</i> , 2021 , 14, e009685	6	7
655	Impella versus extracorporal life support in cardiogenic shock: a propensity score adjusted analysis. <i>ESC Heart Failure</i> , 2021 , 8, 953-961	3.7	3
654	The role of transcatheter mitral valve leaflet approximation for the treatment of secondary mitral regurgitation: current status and future prospects. <i>Expert Review of Medical Devices</i> , 2021 , 18, 261-272	3.5	0
653	Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial. <i>International Journal of Cardiology</i> , 2021 , 334, 37-41	3.2	1
652	Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial. <i>Circulation</i> , 2021 , 144, 1543-1552	16.7	32
651	Impact of Echocardiographic Guidance on Safety and Efficacy of Left Atrial Appendage Closure: An Observational Study. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 1815-1826	5	2
650	Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial.	4.9	2
649	American Heart Journal, 2021, 238, 33-44 Bleeding avoidance strategies in percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2021,	14.8	10
648	Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 1688-1703	5	8
647	Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. <i>New England Journal of Medicine</i> , 2021 , 385, 1643-1655	59.2	46

646	Integrative echocardiographic assessment of patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge repair. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 98, 1404-1412	2.7	O
645	Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial. <i>Circulation</i> , 2021 , 144, 1196-1211	16.7	7
644	Permanent pacemaker implantation late after transcatheter aortic valve implantation. <i>Heart Rhythm</i> , 2021 , 18, 2033-2039	6.7	1
643	Incidence and Outcomes of Infective Endocarditis After Transcatheter or Surgical Aortic Valve Replacement. <i>Journal of the American Heart Association</i> , 2021 , 10, e020368	6	O
642	Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 ,	4.3	O
641	Anatomical and Technical Predictors of Three-Dimensional Mitral Valve Area Reduction After Transcatheter Edge-To-Edge Repair. <i>Journal of the American Society of Echocardiography</i> , 2021 ,	5.8	1
640	3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 1870-1883	5	14
639	Potential Candidates for Transcatheter Tricuspid Valve Intervention After Transcatheter 'Aortic Valve Replacement: Predictors and Prognosis. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 2246-2256	5	1
638	Evaluation of Cerebral Thromboembolism After Transcatheter Aortic Valve Replacement (EARTH TAVR): A Serial Magnetic Resonance Imaging Evaluation as Substudy of the GALILEO Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021 , 14, e011074	6	О
637	Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial. <i>Journal of the American Heart Association</i> , 2021 , 10, e015560	6	3
636	Deep learning-based prediction of early cerebrovascular events after transcatheter aortic valve replacement. <i>Scientific Reports</i> , 2021 , 11, 18754	4.9	O
635	Left ventricular thrombus in ischaemic heart disease: diagnosis, treatment and gaps of knowledge European Heart Journal Quality of Care & Dinical Outcomes, 2021,	4.6	1
634	Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial. <i>Journal of the American Heart Association</i> , 2021 , e023143	6	
633	Clinical benefit of left atrial appendage closure in octogenarians <i>Journal of Geriatric Cardiology</i> , 2021 , 18, 886-896	1.7	
632	Imaging and Patient Selection for Transcatheter Tricuspid Valve Interventions. <i>Frontiers in Cardiovascular Medicine</i> , 2020 , 7, 60	5.4	7
631	ST-elevation myocardial infarction and pulmonary embolism in a patient with COVID-19 acute respiratory distress syndrome. <i>European Heart Journal</i> , 2020 , 41, 2134	9.5	17
630	EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. <i>European Heart Journal</i> , 2020 , 41, 1839-1851	9.5	76
629	Randomized Comparison of Optical Coherence Tomography Versus Angiography to Guide Bioresorbable Vascular Scaffold Implantation: The OPTICO BVS Study. <i>Cardiovascular</i> Revascularization Medicine, 2020 , 21, 1244-1250	1.6	О

(2020-2020)

628	Infective Endocarditis After Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 3020-3030	15.1	26
627	Predictive value of the QFR in detecting vulnerable plaques in non-flow limiting lesions: a combined analysis of the PROSPECT and IBIS-4 study. <i>International Journal of Cardiovascular Imaging</i> , 2020 , 36, 993-1002	2.5	3
626	Optimal Timing of Invasive Coronary Angiography following NSTEMI. <i>Journal of Interventional Cardiology</i> , 2020 , 2020, 8513257	1.8	1
625	Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. <i>Circulation</i> , 2020 , 141, 1618-1627	16.7	48
624	Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020 , 73, 893-901	0.7	4
623	Sex-Specific Management in Patients With Acute Myocardial Infarction and Cardiogenic Shock: A Substudy of the CULPRIT-SHOCK Trial. <i>Circulation: Cardiovascular Interventions</i> , 2020 , 13, e008537	6	18
622	Rationale and design of a prospective, randomized, controlled, multicenter study to evaluate the safety and efficacy of transcatheter heart valve replacement in female patients with severe symptomatic aortic stenosis requiring aortic valve intervention (Randomized researcH in womEn all comers with Aortic stenosis [RHEIA] trial). American Heart Journal, 2020, 228, 27-35	4.9	3
621	Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves. European Heart Journal, 2020, 41, 2731-2742	9.5	46
620	Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial. <i>Circulation</i> , 2020 , 142, 441-454	16.7	40
619	The PASCAL Device-Early Experience with a Leaflet Approximation Device: What Are the Benefits/Limitations Compared with the MitraClip?. <i>Current Cardiology Reports</i> , 2020 , 22, 74	4.2	8
618	Transcatheter Aortic Valve Replacement in Patients With Multivalvular Heart Disease. <i>JACC:</i> Cardiovascular Interventions, 2020 , 13, 1503-1514	5	12
617	Impact of Predilatation Prior to Transcatheter Aortic Valve Implantation With the Self-Expanding Acurate neo Device (from the Multicenter NEOPRO Registry). <i>American Journal of Cardiology</i> , 2020 , 125, 1369-1377	3	5
616	Quantitative flow ratio-guided strategy versus angiography-guided strategy for percutaneous coronary intervention: Rationale and design of the FAVOR III China trial. <i>American Heart Journal</i> , 2020 , 223, 72-80	4.9	18
615	Mechanism of Drug-Eluting Absorbable Metal Scaffold Restenosis: A Serial Optical Coherence Tomography Study. <i>Circulation: Cardiovascular Interventions</i> , 2020 , 13, e008657	6	3
614	Mitral Regurgitation in Low-Flow, Low-Gradient Aortic Stenosis Patients Undergoing TAVR: Insights From the TOPAS-TAVI Registry. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 567-579	5	5
613	Rivaroxaban after transcatheter aortic valve replacement: the GALILEO trial. <i>Cardiovascular Research</i> , 2020 , 116, e39-e41	9.9	2
612	DAPT Score and the Impact of Ticagrelor'Monotherapy During the Second Year After PCI. <i>JACC:</i> Cardiovascular Interventions, 2020 , 13, 634-646	5	6
611	Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. <i>New England Journal of Medicine</i> , 2020 , 382, 1208-1218	59.2	112

610	Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. <i>Atherosclerosis</i> , 2020 , 295, 45-53	3.1	17
609	Outcomes of TTVI in Patients With Pacemaker or Defibrillator Leads: Data From the TriValve Registry. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 554-564	5	12
608	Clinical outcomes of Watchman vs. Amplatzer occluders for left atrial appendage closure (WATCH at LAAC). <i>Europace</i> , 2020 , 22, 916-923	3.9	8
60 7	Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. <i>Clinical Research in Cardiology</i> , 2020 , 109, 930-943	6.1	9
606	Radial versus femoral artery access for percutaneous coronary artery intervention in patients with acute myocardial infarction and multivessel disease complicated by cardiogenic shock: Subanalysis from the CULPRIT-SHOCK trial. <i>American Heart Journal</i> , 2020 , 225, 60-68	4.9	6
605	The impact of pre-procedure heart rate on adverse clinical outcomes in patients undergoing percutaneous coronary intervention: Results from a 2-year follow-up of the GLOBAL LEADERS trial. <i>Atherosclerosis</i> , 2020 , 303, 1-7	3.1	1
604	Outcomes Associated with Respiratory Failure for Patients with Cardiogenic Shock and Acute Myocardial Infarction: A Substudy of the CULPRIT-SHOCK Trial. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
603	Impact of first medical contact to revascularisation time on long-term clinical outcomes in ST-segment elevation myocardial infarction patients. <i>Swiss Medical Weekly</i> , 2020 , 150, w20368	3.1	
602	HAS-BLED score and actual bleeding in elderly patients undergoing transcatheter aortic valve implantation. <i>Minerva Medica</i> , 2020 , 111, 203-212	2.2	2
601	Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2020 , 16, 634-644	3.1	4
600	Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2020 , 15, e1605-e1614	3.1	16
599	Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. <i>EuroIntervention</i> , 2020 , 16, 371-379	3.1	61
598	Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes. <i>EuroIntervention</i> , 2020 , 16, 627-633	3.1	6
597	Clinical outcomes of TAVI or SAVR in men and women with aortic stenosis at intermediate operative risk: a post hoc analysis of the randomised SURTAVI trial. <i>EuroIntervention</i> , 2020 , 16, 833-841	3.1	2
596	The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial. <i>Clinical Research in</i>	6.1	3
595	Cardiology, 2020 , 109, 1125-1139 Levels of evidence supporting drug, device, and other recommendations in the American Heart Association/American College of Cardiology guidelines. <i>American Heart Journal</i> , 2020 , 226, 4-12	4.9	2
594	Frequency and Impact of Bleeding on Outcome in Patients With Cardiogenic Shock. <i>JACC:</i> Cardiovascular Interventions, 2020 , 13, 1182-1193	5	20
593	Shear Stress Estimated by Quantitative Coronary Angiography Predicts Plaques Prone to Progress and Cause Events. <i>JACC: Cardiovascular Imaging</i> , 2020 , 13, 2206-2219	8.4	11

592	A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , 2020 , 382, 120-129	59.2	185
591	Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , 2020 , 382, 130-139	59.2	93
590	Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2020 , 5, 21-29	16.2	23
589	Comparison of clinical outcomes between Magmaris and Orsiro drug eluting stent at 12 months: Pooled patient level analysis from BIOSOLVE II-III and BIOFLOW II trials. <i>International Journal of Cardiology</i> , 2020 , 300, 60-65	3.2	8
588	Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 747-755	3.8	1
5 ⁸ 7	Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. <i>Circulation</i> , 2020 , 141, 781-783	16.7	48
586	Long-term clinical outcomes of Amplatzer cardiac plug versus Amulet occluders for left atrial appendage closure. <i>Catheterization and Cardiovascular Interventions</i> , 2020 , 96, E324-E331	2.7	8
585	Association of ECG parameters with late gadolinium enhancement and outcome in patients with clinical suspicion of acute or subacute myocarditis referred for CMR imaging. <i>PLoS ONE</i> , 2020 , 15, e022	7 1 34	11
584	Sudden Cardiac Death in Ischemic Heart Disease: From Imaging Arrhythmogenic Substrate to Guiding Therapies. <i>JACC: Cardiovascular Imaging</i> , 2020 , 13, 2223-2238	8.4	4
583	Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 222-230	6.4	4
582	Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020 , 96, 1369-1378	2.7	3
581	Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: A contemporary analysis from the SPUM-ACS cohort. <i>International Journal of Cardiology</i> , 2020 , 303, 8-13	3.2	4
580	Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial. <i>Clinical Research in Cardiology</i> , 2020 , 109, 918	-92 ¹ 9	2
579	Prognosis of Patients with Chronic and Hospital-Acquired Anaemia After Acute Coronary Syndromes. <i>Journal of Cardiovascular Translational Research</i> , 2020 , 13, 618-628	3.3	2
578	Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 22-30	6.4	3
577	How to shape the future of cardiology and cardiac surgery?. European Heart Journal, 2020, 41, 3693-370	1 5.5	5
576	Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. <i>Cardiovascular Diabetology</i> , 2020 , 19, 179	8.7	4
575	Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents for Primary PCI: A Subgroup Analysis of the BIOSTEMI Randomized Trial. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 2314-2316	5	

574	Antidepressant treatment in patients following acute coronary syndromes: a systematic review and Bayesian meta-analysis. <i>ESC Heart Failure</i> , 2020 , 7, 3610	3.7	6
573	Pulmonary Artery Pressure Ventricularization in a Patient With Carcinoid Heart Disease. <i>JACC: Case Reports</i> , 2020 , 2, 1200-1204	1.2	
572	Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. <i>European Heart Journal</i> , 2020 , 41, 3743-3749	9.5	45
571	Mortality, Stroke, and Hospitalization Associated With Deferred vs Expedited Aortic Valve Replacement in Patients Referred for Symptomatic Severe Aortic Stenosis During the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2020 , 3, e2020402	10.4	15
57°	One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients. <i>Circulation: Cardiovascular Interventions</i> , 2020 , 13, e009565	6	17
569	Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: Insights from the GLOBAL LEADERS trial. <i>International Journal of Cardiology</i> , 2020 , 320, 27-34	3.2	2
568	A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making. <i>American Heart Journal</i> , 2020 , 223, 44-47	4.9	8
567	Predictors of Outcomes Following Transcatheter Edge-to-Edge Mitral Valve Repair. <i>JACC:</i> Cardiovascular Interventions, 2020 , 13, 1733-1748	5	6
566	Impact of Left Ventricular Outflow Tract Calcification on Procedural Outcomes After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 1789-1799	5	19
565	Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020 , 13, e006660	5.8	6
564	Randomized Trials Versus Common´Sense and Clinical Observation: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 580-589	15.1	22
563	Coronary Access After TAVR-in-TAVR as Evaluated by Multidetector Computed Tomography. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 2528-2538	5	21
562	ESC Committee for Practice Guidelines: providing knowledge to everyday clinical practice. <i>Cardiovascular Research</i> , 2020 , 116, e146-e148	9.9	1
561	Evaluation of Cumulative Meta-analysis of Rare Events as a Tool for Clinical Trials Safety Monitoring. <i>JAMA Network Open</i> , 2020 , 3, e2015031	10.4	1
560	Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020 , 13, e009177	6	5
559	The relationship between baseline diastolic dysfunction and postimplantation invasive hemodynamics with transcatheter aortic valve replacement. <i>Clinical Cardiology</i> , 2020 , 43, 1428-1434	3.3	1
558	Bicuspid Aortic Valve Morphology and Outcomes After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2020 , 76, 1018-1030	15.1	50
557	PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 .	6.4	13

556	Impact of White Blood Cell Count on Clinical Outcomes in Patients Treated with Aspirin-Free Ticagrelor Monotherapy after Percutaneous Coronary Intervention: Insights from the GLOBAL LEADERS Trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	6.4	4
555	Predilatation and paravalvular leakage risk in TAVR - AuthorsNeply. <i>Lancet, The</i> , 2020 , 396, 600-601	40	
554	Impact of Massive or Torrential Tricuspid Regurgitation in Patients Undergoing Transcatheter Tricuspid Valve Intervention. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 1999-2009	5	18
553	Valvular and Nonvalvular Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 2124-2133	5	4
552	Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial. <i>Trials</i> , 2020 , 21, 770	2.8	14
551	Comparison of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents and Thin, Durable-Polymer Everolimus-Eluting Stents in Calcified or Small Vessel Lesions. <i>Circulation: Cardiovascular Interventions</i> , 2020 , 13, e009189	6	2
550	Transcatheter Aortic Valve Replacement: Role of Multimodality Imaging in Common and Complex Clinical Scenarios. <i>JACC: Cardiovascular Imaging</i> , 2020 , 13, 124-139	8.4	9
549	Prognostic values of fasting hyperglycaemia in non-diabetic patients with acute coronary syndrome: A prospective cohort study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020 , 9, 589-	5 9 8	6
548	Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020 , 96, 100-111	2.7	7
547	Does isolated mitral annular calcification in the absence of mitral valve disease affect clinical outcomes after transcatheter aortic valve replacement?. European Heart Journal Cardiovascular Imaging, 2020 , 21, 522-532	4.1	12
546	Incidence, predictors, and relevance of acute kidney injury in patients undergoing left atrial appendage closure with Amplatzer occluders: a multicentre observational study. <i>Clinical Research in Cardiology</i> , 2020 , 109, 444-453	6.1	7
545	Utility of Multimodality Intravascular Imaging and the Local Hemodynamic Forces to Predict Atherosclerotic Disease Progression. <i>JACC: Cardiovascular Imaging</i> , 2020 , 13, 1021-1032	8.4	12
544	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>European Heart Journal</i> , 2020 , 41, 407-477	9.5	1835
543	Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020 , 96, E516-E526	2.7	3
542	Hemodynamic Relevance of Anomalous Coronary Arteries Originating From the Opposite Sinus of Valsalva-In Search of the Evidence. <i>Frontiers in Cardiovascular Medicine</i> , 2020 , 7, 591326	5.4	8
541	Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial). <i>American Journal of Cardiology</i> , 2019 , 124, 1833-1840	3	3
540	Current Generation Balloon-Expandable Transcatheter Valve Positioning Strategies During Aortic Valve-in-Valve Procedures and Clinical Outcomes. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 1606-16	17	5
539	Clinical Outcomes Following Implantation of Thin-Strut, Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY Stents. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e008152	6	30

538	Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. <i>Lancet, The</i> , 2019 , 394, 1243-1253	40	78
537	Evolocumab for Early Reduction of LDL´Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2452-2462	15.1	56
536	Transcatheter Versus Medical Treatment of Patients With Symptomatic Severe Tricuspid Regurgitation. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2998-3008	15.1	127
535	Prosthesis-Patient Mismatch Following Transcatheter Aortic Valve Replacement With Supra-Annular and Intra-Annular Prostheses. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 2173-2182	5	26
534	Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial. <i>JAMA Cardiology</i> , 2019 , 4, 1092-1101	16.2	63
533	Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. <i>Circulation</i> , 2019 , 140, 1921-1932	16.7	40
532	Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial. <i>Circulation</i> , 2019 , 140, 1960-1963	16.7	6
531	The hospital results and 1-year outcomes of transcatheter aortic valve-in-valve procedures and transcatheter aortic valve implantations in the native valves: the results from the Swiss-TAVI Registry. <i>European Journal of Cardio-thoracic Surgery</i> , 2019 , 56, 55-63	3	18
530	Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1 month of dual antiplatelet therapy. American Heart Journal, 2019 , 214, 134-141	4.9	24
529	Time-Dependent Myocardial Necrosis in Patients With ST-Segment-Elevation Myocardial Infarction Without Angiographic Collateral Flow Visualized by Cardiac Magnetic Resonance Imaging: Results From the Multicenter STEMI-SCAR Project. <i>Journal of the American Heart Association</i> , 2019 , 8, e012429	6	17
528	Dyspnoea in the GLOBAL LEADERS trial - AuthorsNeply. <i>Lancet, The</i> , 2019 , 393, 2393-2394	40	1
527	Edge-to-Edge Mitral Valve Repair With Extended Clip Arms: Early Experience From a Multicenter Observational Study. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 1356-1365	5	46
526	Biodegradable-polymer stents versus durable-polymer stents - AuthorsNeply. <i>Lancet, The</i> , 2019 , 393, 1933	40	1
525	Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. <i>European Heart Journal</i> , 2019 , 40, 3143-2	3 75 3	150
524	Effect of stent diameter in women undergoing percutaneous coronary intervention with early- and new-generation drug-eluting stents: From the WIN-DES collaboration. <i>International Journal of Cardiology</i> , 2019 , 287, 59-61	3.2	3
523	Mitral regurgitation in heart failure: time for a rethink. European Heart Journal, 2019, 40, 2189-2193	9.5	28
522	Validation of High-Risk Features for Stent-Related Ischemic Events as Endorsed by the 2017 DAPT Guidelines. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 820-830	5	21
521	Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. <i>Lancet, The</i> , 2019 , 393, 2503-2510	40	87

520	Impact of left ventricular function on clinical outcomes among patients with coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 1273-1284	3.9	6
519	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2019 , 380, 1509-1524	59.2	538
518	Implications of the local haemodynamic forces on the phenotype of coronary plaques. <i>Heart</i> , 2019 , 105, 1078-1086	5.1	9
517	Transcatheter Aortic Valve Replacement With Next-Generation Self-Expanding Devices: A Multicenter, Retrospective, Propensity-Matched Comparison of Evolut PRO Versus Acurate neo Transcatheter Heart Valves. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 433-443	5	34
516	Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention. <i>PLoS ONE</i> , 2019 , 14, e0211464	3.7	2
515	Five-year clinical outcomes and intracoronary imaging findings of the COMFORTABLE AMI trial: randomized comparison of biodegradable polymer-based biolimus-eluting stents with bare-metal stents in patients with acute ST-segment elevation myocardial infarction. European Heart Journal,	9.5	17
514	Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY). <i>BMJ Open</i> , 2019 , 9, e026053	3	15
513	Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 1069-1080	27.4	79
512	Long-term outcomes with balloon-expandable and self-expandable prostheses in patients undergoing transfemoral transcatheter aortic valve implantation for severe aortic stenosis. <i>International Journal of Cardiology</i> , 2019 , 290, 45-51	3.2	7
511	Valvular Resistance and Bleeding Events Among Patients Undergoing Transcatheter Aortic Valve Replacement. <i>Structural Heart</i> , 2019 , 3, 220-228	0.6	
510	Impact of valvular resistance on aortic regurgitation after transcatheter aortic valve replacement according to the type of prosthesis. <i>Clinical Research in Cardiology</i> , 2019 , 108, 1343-1353	6.1	2
509	Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes. <i>European Journal of Clinical Investigation</i> , 2019 , 49, e13117	4.6	12
508	1-Year Outcomes of the CENTERA-EU Trial Assessing a Novel Self-Expanding Transcatheter Heart Valve. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 673-680	5	6
507	Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study. <i>International Journal of Cardiology</i> , 2019 , 286, 43-50	3.2	13
506	Usefulness of Clopidogrel Loading in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the BRAVO-3 Randomized Trial). <i>American Journal of Cardiology</i> , 2019 , 123, 1494-15	6 0	10
505	Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. Journal of the American College of Cardiology, 2019 , 73, 741-754	15.1	123
504	Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 758-774	15.1	11
503	Fourth universal definition of myocardial infarction (2018) European Heart Journal, 2019 , 40, 237-269	9.5	851

502	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2019 , 40, 87-165	9.5	2408
501	Considerations for the choice between coronary artery bypass grafting and percutaneous coronary intervention as revascularization strategies in major categories of patients with stable multivessel coronary artery disease: an accompanying article of the task force of the 2018 ESC/EACTS	9.5	36
500	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2019 , 55, 4-90	3	251
499	Angiographic derived endothelial shear stress: a new predictor of atherosclerotic disease progression. <i>European Heart Journal Cardiovascular Imaging</i> , 2019 , 20, 314-322	4.1	5
498	Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). <i>European Heart Journal</i> , 2019 , 40, 2070-2085	9.5	35
497	Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e007734	6	3
496	1-Year Outcomes After Edge-to-Edge Valve Repair for Symptomatic Tricuspid Regurgitation: Results From the TriValve Registry. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 1451-1461	5	74
495	Long-Term Outcomes of the FORMA Transcatheter Tricuspid Valve Repair System for the Treatment of Severe Tricuspid Regurgitation: Insights From the First-in-Human Experience. <i>JACC:</i> Cardiovascular Interventions, 2019, 12, 1438-1447	5	21
494	Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e0080	6)24	12
493	Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. <i>European Heart Journal</i> , 2019 , 40, 2595-2604	9.5	51
492	Management of Conduction Disturbances 'Associated With Transcatheter Aortic Valve Replacement: JACC Scientific Expert Panel. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 108	ห6 ⁻ 1ี่?ี่ใ0€	5 111
491	Case report of simultaneous transcatheter mitral valve-in-valve implantation and percutaneous closure of two paravalvular leaks. <i>European Heart Journal - Case Reports</i> , 2019 , 3, ytz123	0.9	5
490	Prevention, Diagnosis, and Management of Radiation-Associated Cardiac Disease: JACC Scientific Expert Panel. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 905-927	15.1	53
489	Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical Practice. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 16	6 5 -167	·5 ¹⁴
488	Non-Linear Relationship between Anti-Apolipoprotein A-1 IgGs and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	7
4 ⁸ 7	Efficacy and Safety of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin, Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization of Patients With Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2019 , 124, 1020-1026	3	7
486	Surgical Transatrial Implantation of Transcatheter Heart Valves in Severe Mitral Annular Calcification. <i>Interventional Cardiology Clinics</i> , 2019 , 8, 313-319	1.4	4
4 ⁸ 5	Percutaneous Mitral Edge-to-Edge Repair: State of the Art and a Glimpse to the Future. <i>Frontiers in Cardiovascular Medicine</i> , 2019 , 6, 122	5.4	9

(2019-2019)

484	aortic valve replacement in patients with symptomatic severe aortic stenosis: a randomised non-inferiority trial. <i>Lancet, The</i> , 2019 , 394, 1619-1628	40	94
483	Diabetes and baseline glucose are associated with inflammation, left ventricular function and short- and long-term outcome in acute coronary syndromes: role of the novel biomarker Cyr 61. <i>Cardiovascular Diabetology</i> , 2019 , 18, 142	8.7	13
482	Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2223-2234	15.1	51
481	Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2015-2027	15.1	16
480	Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 1954-1962	5	23
479	Diagnosis and Management of Anomalous Coronary Arteries with a Malignant Course. <i>Interventional Cardiology Review</i> , 2019 , 14, 83-88	4.2	23
478	Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2019 , 15, e539-e546	3.1	9
477	Interventional cardiologyN golden age of contributions to evidence-based medicine. <i>EuroIntervention</i> , 2019 , 15, 31-34	3.1	3
476	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>EuroIntervention</i> , 2019 , 14, 1435-1534	3.1	180
475	Clinical outcomes in high-risk patients with a severe aortic stenosis: a seven-year follow-up analysis. <i>Swiss Medical Weekly</i> , 2019 , 149, w20013	3.1	1
474	Interventional treatment of mitral valve regurgitation: an alternative to surgery?. <i>Swiss Medical Weekly</i> , 2019 , 149, w20023	3.1	O
473	2019 - A leap year for valvular heart disease. <i>EuroIntervention</i> , 2019 , 15, 821-823	3.1	
472	Will the Evolut Low Risk trial change my practice?. EuroIntervention, 2019, 15, e1072-e1076	3.1	
471	Are all DES equal at 10-year follow-up?. EuroIntervention, 2019, 15, e945-e947	3.1	
470	Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2572-2584	15.1	18
469	Ischemia and Bleeding in Cancer Patients Undergoing Percutaneous Coronary Intervention. <i>JACC:</i> CardioOncology, 2019 , 1, 145-155	3.8	6
468	Outcomes After Current Transcatheter Tricuspid Valve Intervention: Mid-Term Results From the International TriValve Registry. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 155-165	5	141
467	Rationale and design for AMPLATZER Amulet Left Atrial Appendage Occluder IDE randomized controlled trial (Amulet IDE Trial). <i>American Heart Journal</i> , 2019 , 211, 45-53	4.9	17

466	Changes in Coronary Plaque Composition in Patients With Acute Myocardial Infarction Treated With High-Intensity Statin Therapy (IBIS-4): A Serial Optical Coherence Tomography Study. <i>JACC: Cardiovascular Imaging</i> , 2019 , 12, 1518-1528	8.4	31
465	Outcomes From Transcatheter Aortic Valve Replacement in Patients With Low-Flow, Low-Gradient Aortic Stenosis and Left Ventricular Ejection Fraction Less Than 30%: A Substudy From the TOPAS-TAVI Registry. <i>JAMA Cardiology</i> , 2019 , 4, 64-70	16.2	37
464	Transcatheter aortic valve replacement in patients with concomitant mitral stenosis. <i>European Heart Journal</i> , 2019 , 40, 1342-1351	9.5	14
463	Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study. <i>American Heart Journal</i> , 2019 , 209, 97-105	4.9	39
462	Temporal trends in adoption and outcomes of transcatheter aortic valve implantation: a SwissTAVI Registry analysis. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019 , 5, 242-251	4.6	29
461	Electrocardiographic predictors of mortality in patients after percutaneous coronary interventions - a nested case-control study. <i>Acta Cardiologica</i> , 2019 , 74, 341-349	0.9	1
460	Percutaneous patent foramen ovale closure during live case demonstrations. <i>Catheterization and Cardiovascular Interventions</i> , 2019 , 93, 982-988	2.7	
459	Application of the MADS classification system in a "mega mammoth" stent trial: Feasibility and preliminary clinical implications. <i>Catheterization and Cardiovascular Interventions</i> , 2019 , 93, 57-63	2.7	5
458	Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates. <i>International Journal of Cardiology</i> , 2019 , 277, 60-65	3.2	1
457	Prognostic Value of Right Ventricular Dysfunction on Clinical Outcomes After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Imaging</i> , 2019 , 12, 577-587	8.4	41
456	Computed tomography detection and quantification of left atrial appendage residual patency as collateral finding after percutaneous closure. <i>International Journal of Cardiology</i> , 2018 , 260, 42-46	3.2	5
455	The Impact of Left Ventricular Diastolic Dysfunction on Clinical Outcomes After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 593-601	5	34
454	Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST-Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	7
453	Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. <i>International Journal of Cardiology</i> , 2018 , 263, 24-28	3.2	6
452	Improvement of Risk Prediction After Transcatheter Aortic Valve Replacement by Combining Frailty With Conventional Risk Scores. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 395-403	5	50
451	Early versus newer generation devices for transcatheter aortic valve implantation in routine clinical practice: a propensity score matched analysis. <i>Open Heart</i> , 2018 , 5, e000695	3	24
450	Gull ESC/EACTS 2017 sobre el tratamiento de las valvulopatlis. <i>Revista Espanola De Cardiologia</i> , 2018 , 71, 110.e1-110.e47	1.5	22
449	Loss of Sirt3 accelerates arterial thrombosis by increasing formation of neutrophil extracellular traps and plasma tissue factor activity. <i>Cardiovascular Research</i> , 2018 , 114, 1178-1188	9.9	27

448	Incidence, predictors and clinical outcomes of residual stenosis after aortic valve-in-valve. <i>Heart</i> , 2018 , 104, 828-834	5.1	39
447	Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 68-76	5	18
446	New-onset arrhythmias following transcatheter aortic valve implantation: a systematic review and meta-analysis. <i>Heart</i> , 2018 , 104, 1208-1215	5.1	21
445	Influence of operator experience and PCI volume on transfemoral access techniques: A collaboration of international cardiovascular societies. <i>Cardiovascular Revascularization Medicine</i> , 2018 , 19, 143-150	1.6	1
444	Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management: Data From the Randomized MATRIX-Access Trial. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 36-50	5	30
443	Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 53-65	5	13
442	Actualizacifi ESC 2017 sobre el tratamiento antiagregante plaquetario doble en la enfermedad coronaria, desarrollada en colaboracifi con la EACTS. <i>Revista Espanola De Cardiologia</i> , 2018 , 71, 42.e1-42	.ē58	2
441	Patent foramen ovale closure vs. medical therapy for recurrent stroke prevention: Evolution of treatment effect during follow-up. <i>International Journal of Cardiology</i> , 2018 , 255, 29-31	3.2	6
440	Early Detection of Subclinical Myocardial Damage in Chronic Aortic Regurgitation and Strategies for Timely Treatment of Asymptomatic Patients. <i>Circulation</i> , 2018 , 137, 184-196	16.7	26
439	Nonejecting Hearts on Femoral Veno-Arterial Extracorporeal Membrane Oxygenation: Aortic Root Blood Stasis and Thrombus Formation-A Case Series and Review of the Literature. <i>Critical Care Medicine</i> , 2018 , 46, e459-e464	1.4	29
438	Current Use of Intracoronary Imaging in Interventional Practice - Results of a European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Japanese Association of Cardiovascular Interventions and Therapeutics (CVIT) Clinical Practice Survey. <i>Circulation Journal</i> , 2018 , 82, 1360-1368	2.9	21
437	Expansion of transcatheter aortic valve implantation: new indications and socio-economic considerations. <i>European Heart Journal</i> , 2018 , 39, 2643-2645	9.5	12
436	An open-Label, 2 12 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial.	4.9	56
435	American Heart Journal, 2018 , 200, 17-23 New prospects for PCSK9 inhibition?. European Heart Journal, 2018 , 39, 2600-2601	9.5	9
434	Transcatheter Aortic Valve Replacement in Patients With Low-Flow, Low-Gradient Aortic Stenosis: The TOPAS-TAVI Registry. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1297-1308	15.1	88
433	Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes. Journal of the American College of Cardiology, 2018 , 71, 1231-1242	15.1	27
432	Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018 , 7, 129-138	4.3	52
431	Concerns about the European Society of Cardiology atrial fibrillation guidelines: reply. <i>Europace</i> , 2018 , 20, 216	3.9	

430	Baseline serum bicarbonate levels independently predict short-term mortality in critically ill patients with ischaemic cardiogenic shock. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018 , 7, 45-52	4.3	18
429	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic	9.5	1475
428	Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. <i>European Heart Journal</i> , 2018 , 39, 1591-1601	9.5	31
427	2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. <i>European Heart Journal</i> , 2018 , 39, 1131-1143	9.5	132
426	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2018 , 53, 34-78	3	149
425	Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. <i>European Heart Journal</i> , 2018 , 39, 1172-1180	9.5	93
424	From bare metal to barely anything: an update on coronary stenting. <i>Heart</i> , 2018 , 104, 533-540	5.1	3
423	Low-Dose Aspirin to Reduce the Risk for Myocardial Infarction Among Patients With Coronary Stents Undergoing Noncardiac Surgery. <i>Annals of Internal Medicine</i> , 2018 , 168, 289-290	8	
422	Impact of total ischemic time on manual thrombus aspiration benefit during primary percutaneous coronary intervention. <i>American Heart Journal</i> , 2018 , 204, 34-42	4.9	2
421	Prognostic value of pulse pressure after an acute coronary syndrome. <i>Atherosclerosis</i> , 2018 , 277, 219-22	26 .1	11
420	Outcomes of non-invasive diagnostic modalities for the detection of coronary artery disease: network meta-analysis of diagnostic randomised controlled trials. <i>BMJ, The</i> , 2018 , 360, k504	5.9	56
419	Feasibility of cardiovascular magnetic resonance to detect oxygenation deficits in patients with multi-vessel coronary artery disease triggered by breathing maneuvers. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2018 , 20, 31	6.9	26
418	Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry. <i>Circulation: Cardiovascular Interventions</i> , 2018 , 11, e006132	6	26
4 1 7	Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2018 , 205, 110-117	4.9	17
416	Angiographic late lumen loss revisited: impact on long-term target lesion revascularization. <i>European Heart Journal</i> , 2018 , 39, 3381-3389	9.5	17
415	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. <i>Lancet, The</i> , 2018 , 392, 835-848	40	129
414	One-Year Outcomes after PCI Strategies in Cardiogenic Shock. <i>New England Journal of Medicine</i> , 2018 , 379, 1699-1710	59.2	194
413	Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. <i>Lancet, The</i> , 2018 , 392, 737-746	40	71

412	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. <i>Lancet</i> ,	40	356
411	The, 2018 , 392, 940-949 Fluoroscopic Anatomy of Right-Sided Heart Structures for Transcatheter Interventions. <i>JACC:</i> Cardiovascular Interventions, 2018 , 11, 1614-1625	5	15
410	Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. <i>European Heart Journal</i> , 2018 , 39, 2192-2207	9.5	91
409	Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. <i>Circulation</i> , 2018 , 137, 2635-2650	16.7	172
408	A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. EuroIntervention, 2018, 14, 692-699	3.1	7
407	Stent Technology 2018 , 137-159		
406	Incidence and impact of renal dysfunction on clinical outcomes after transcatheter aortic valve implantation. <i>International Journal of Cardiology</i> , 2018 , 250, 73-79	3.2	6
405	Circadian dependence of manual thrombus aspiration benefit in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>Clinical Research in Cardiology</i> , 2018 , 107, 338-346	6.1	6
404	Postprocedural high-sensitivity troponin T and prognosis in patients with non-ST-segment elevation myocardial infarction treated with early percutaneous coronary intervention. <i>Cardiovascular Revascularization Medicine</i> , 2018 , 19, 480-486	1.6	3
403	Transcatheter aortic valve thrombosis: incidence, clinical presentation and long-term outcomes. <i>European Heart Journal Cardiovascular Imaging</i> , 2018 , 19, 398-404	4.1	26
402	Incidence, predictors, and clinical outcomes of coronary obstruction following transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: insights from the VIVID registry. <i>European Heart Journal</i> , 2018 , 39, 687-695	9.5	158
401	Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial. <i>Clinical Cardiology</i> , 2018 , 41, 1513-15	52 ³ 0 ³	14
400	Prognostic Impact of Periprocedural Myocardial Infarction in Patients Undergoing Elective Percutaneous Coronary Interventions. <i>Circulation: Cardiovascular Interventions</i> , 2018 , 11, e006752	6	15
399	Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization. <i>Circulation: Cardiovascular Interventions</i> , 2018 , 11, e006741	6	10
398	Prognostic Value of SYNTAX Score II in Patients with Acute Coronary Syndromes Referred for Invasive Management: A Subanalysis from the SPUM and COMFORTABLE AMI Cohorts. <i>Cardiology Research and Practice</i> , 2018 , 2018, 9762176	1.9	5
397	Sheathless Transcaval Transcatheter Aortic Valve Implantation Through an Abdominal Aortic Graft. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 1688.e17-1688.e19	3.8	2
396	Interpretation of results of pooled analysis of individual patient data. <i>Lancet, The</i> , 2018 , 392, 817-818	40	
395	Progression of cardiac allograft vasculopathy assessed by serial three-vessel quantitative coronary angiography. <i>PLoS ONE</i> , 2018 , 13, e0202950	3.7	2

394	Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 1576-1586	5	28
393	Long-Term Coronary Functional Assessment of the Infarct-Related Artery Treated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents: Insights of the TROFI II Trial. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 1559-1571	5	22
392	Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent: 5-Year Outcomes of the Randomized BIOFLOW-II Trial. <i>JACC:</i> Cardiovascular Interventions, 2018 , 11, 995-1002	5	45
391	Adenosine and Ticagrelor Plasma Levels in Patients With and Without Ticagrelor-Related Dyspnea. <i>Circulation</i> , 2018 , 138, 646-648	16.7	19
390	Implications of the local hemodynamic forces on the formation and destabilization of neoatherosclerotic lesions. <i>International Journal of Cardiology</i> , 2018 , 272, 7-12	3.2	8
389	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <i>Nature Reviews Cardiology</i> , 2018 , 15, 480-496	14.8	134
388	Transfemoral aortic valve implantation of Edwards SAPIEN 3 without predilatation. <i>Catheterization and Cardiovascular Interventions</i> , 2017 , 89, E38-E43	2.7	21
387	First-in-Human Evaluation of a Novel Polymer-Free Drug-Filled Stent: Angiographic, IVUS, OCT, and Clinical Outcomes From the RevElution Study. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 147-156	5	28
386	Misconceptions and Facts About Aortic Stenosis. <i>American Journal of Medicine</i> , 2017 , 130, 398-402	2.4	1
385	Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. <i>American Heart Journal</i> , 2017 , 184, 81-87	4.9	78
384	Increased Proangiogenic Activity of Mobilized CD34+ Progenitor Cells of Patients With Acute ST-Segment-Elevation Myocardial Infarction: Role of Differential MicroRNA-378 Expression. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017 , 37, 341-349	9.4	28
383	Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. <i>European Heart Journal</i> , 2017 , 38, 814-824	9.5	226
382	Impact of chronic kidney disease on 2-year clinical outcomes in patients treated with 6-month or 24-month DAPT duration: An analysis from the PRODIGY trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017 , 90, E73-E84	2.7	14
381	Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. <i>Lancet, The,</i> 2017 , 389, 1025-1034	40	543
380	Myocardial revascularization in patients with left main or multivessel coronary artery disease at high surgical risk: conventional wisdom versus risk prediction model. <i>European Journal of Cardio-thoracic Surgery</i> , 2017 , 51, 949-951	3	2
379	No significant gender difference in hospitalizations for acute coronary syndrome in Switzerland over the time period of 2001 to 2010. <i>International Journal of Cardiology</i> , 2017 , 243, 59-64	3.2	
378	Rates and predictors of hospital readmission after transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2017 , 38, 2211-2217	9.5	31
377	Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis. <i>European Journal of Cardio-thoracic Surgery</i> , 2017 , 52, 206-217	3	23

(2017-2017)

376	The impact of functional vs degenerative mitral regurgitation on clinical outcomes among patients undergoing transcatheter aortic valve implantation. <i>American Heart Journal</i> , 2017 , 184, 71-80	4.9	18
375	Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017 , 90, 1016-1026	2.7	3
374	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management: AKI-MATRIX. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2592-2592	15.1	95
373	Latest evidence on transcatheter aortic valve implantation vs. surgical aortic valve replacement for the treatment of aortic stenosis in high and intermediate-risk patients. <i>Current Opinion in Cardiology</i> , 2017 , 32, 117-122	2.1	8
372	Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: A study of age- and gender-matched cohorts. <i>International Journal of Cardiology</i> , 2017 , 243, 150-155	3.2	17
371	Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention. <i>Annals of Internal Medicine</i> , 2017 , 167, 17-25	8	30
370	Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation. <i>European Heart Journal</i> , 2017 , 38, 1069-1080	9.5	38
369	Rationale and design of the Hunting for the off-target properties of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) trial. <i>American Heart Journal</i> , 2017 , 189, 128-136	4.9	7
368	Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. <i>New England Journal of Medicine</i> , 2017 , 376, 1321-1331	59.2	1524
367	Radiation Exposure and Vascular Access în Acute Coronary Syndromes: The RAD-Matrix Trial. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2530-2537	15.1	41
366	Impact of Patient and Lesion Complexity on Long-Term Outcomes Following Coronary Revascularization With New-Generation Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2017 , 119, 501-507	3	7
365	Mechanisms of Very Late Bioresorbable Scaffold Thrombosis: The INVEST Registry. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2330-2344	15.1	89
364	PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. <i>New England Journal of Medicine</i> , 2017 , 377, 2419-2432	59.2	466
363	Predictors of 1-Year Mortality After Transcatheter Aortic Valve Implantation in Patients With and Without Advanced Chronic Kidney Disease. <i>American Journal of Cardiology</i> , 2017 , 120, 2025-2030	3	12
362	2017 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Journal of Cardio-thoracic Surgery</i> , 2017 , 52, 616-664	3	359
361	2017 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Heart Journal</i> , 2017 , 38, 2739-2791	9.5	3615
360	A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the treatment of female patients with de novo coronary artery lesions: The SPIRIT WOMEN study. <i>PLoS ONE</i> , 2017 , 12, e0182632	3.7	3
359	Transcatheter Mitral Valve Replacement for Degenerated Bioprosthetic Valves and Failed Annuloplasty Rings. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1121-1131	15.1	134

358	Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 1621-1630	5	11
357	2-Year Outcomes After Transcatheter Mitral Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 1671-1678	5	28
356	Geographical differences in the ratio of percutaneous and surgical myocardial revascularization procedures in the treatment of coronary artery disease. <i>European Journal of Cardio-thoracic Surgery</i> , 2017 , 52, 454-455	3	2
355	Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies. <i>Drugs</i> , 2017 , 77, 1733-1754	12.1	13
354	Evolving Indications for Transcatheter Aortic Valve Interventions. <i>Current Cardiology Reports</i> , 2017 , 19, 107	4.2	11
353	Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 1867-1877	5	10
352	Orsiro cobalt-chromium sirolimus-eluting stent: present and future perspectives. <i>Expert Review of Medical Devices</i> , 2017 , 14, 773-788	3.5	20
351	Serial 5-Year Evaluation of Side Branches Jailed by Bioresorbable Vascular Scaffolds Using 3-Dimensional Optical Coherence Tomography: Insights From the ABSORB Cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of	6	6
350	Bioresorbable scaffolds: in search of event-free dissolution. <i>Lancet, The</i> , 2017 , 390, 720-722	40	
349	Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the	9.5	198
348	Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the	3	88
347	Frequency, Timing, and Impact of Access-Site and Non-Access-Site Bleeding on Mortality Among Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 1436-1446	5	57
346	Thrombo-embolic prevention after transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2017 , 38, 3341-3350	9.5	41
345	Transcatheter Tricuspid Valve Repair With a New Transcatheter Coaptation System for the Treatment of Severe Tricuspid Regurgitation: 1-Year Clinical and Echocardiographic Results. <i>JACC:</i> Cardiovascular Interventions, 2017 , 10, 1994-2003	5	71
344	Clinical Outcomes With a Repositionable Self-Expanding Transcatheter Aortic Valve Prosthesis: The International FORWARD Study. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 845-853	15.1	101
343	Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study. <i>Lancet, The</i> , 2017 , 390, 773-780	40	136
342	Long-term outcomes after acute myocardial infarction in countries with different socioeconomic environments: an international prospective cohort study. <i>BMJ Open</i> , 2017 , 7, e012715	3	6
341	Rehospitalizations Following Primary Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction: Results From a Multi-Center Randomized Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	4

340	Transfemoral Approach for Coronary Angiography and Intervention: A Collaboration of International Cardiovascular Societies. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 2269-2279	5	17
339	Predicting Mortality After Transcatheter Aortic Valve Replacement: External Validation of the Transcatheter Valve Therapy Registry Model. <i>Circulation: Cardiovascular Interventions</i> , 2017 , 10,	6	21
338	Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 60-74	15.1	39
337	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. <i>JAMA Cardiology</i> , 2017 , 2, 855-862	16.2	18
336	Pitfalls in TAMVI: experience with the repositionable Lotus Valve System. <i>Journal of Cardiothoracic Surgery</i> , 2017 , 12, 47	1.6	1
335	Self-Expanding Transcatheter Aortic Valve System for Symptomatic High-Risk Patients With Severe Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 3127-3136	15.1	33
334	Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes. <i>European Heart Journal</i> , 2017 , 38, 3493-350	2 ^{.5}	33
333	Atrial Fibrillation on Vitamin K Antagonist Undergoing Elective Percutaneous Coronary Intervention for Stable Effort Angina 2017 , 1-18		
332	Sports engagement and age at first myocardial infarction in men under 55 years of age. <i>PLoS ONE</i> , 2017 , 12, e0184035	3.7	
331	Profiling and validation of circulating microRNAs for cardiovascular events in patients presenting with ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2017 , 38, 511-515	9.5	53
330	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European	9.5	3850
329	Society of Cardiology (ESC). European Heart Journal, 2016, 37, 267-315 Causes of late mortality with dual antiplatelet therapy after coronary stents. European Heart Journal, 2016, 37, 378-85	9.5	31
328	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016 , 37, 2893-2962	9.5	4465
327	Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease: A Subgroup Analysis of the PRODIGY Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2016 , 1, 795-803	16.2	48
326	Impact of Sex on 2-Year Clinical Outcomes în Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial. <i>JACC:</i> Cardiovascular Interventions, 2016 , 9, 1780-9	5	18
325	Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial. <i>European Heart Journal</i> , 2016 , 37, 3386-3395	9.5	64
324	Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the PRISM Trial. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1667-76	5	3
323	Pre-hospital alarm activation for STEMI patients undergoing primary percutaneous coronary intervention in the era of transradial procedures. <i>European Journal of Internal Medicine</i> , 2016 , 35, 83-88	3.9	1

322	Nonbacterial thrombotic endocarditis presenting as intracerebral hemorrhage. <i>Wiener Klinische Wochenschrift</i> , 2016 , 128, 922-924	2.3	11
321	Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1890-901	5	23
320	"One-Stop Shop": Safety of Combining Transcatheter Aortic Valve Replacement and Left Atrial Appendage Occlusion. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1487-95	5	16
319	Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1473-83	5	20
318	Transcatheter Aortic Valve Replacement for the Treatment of Pure Native Aortic Valve Regurgitation: A Systematic Review. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 2308-2317	5	68
317	Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. <i>Lancet, The</i> , 2016 , 388, 2479-2491	40	352
316	Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. <i>BMJ, The</i> , 2016 , 354, i4935	5.9	36
315	Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. <i>BMJ, The</i> , 2016 , 355, i5483	5.9	34
314	Uptake and efficacy of a systematic intensive smoking cessation intervention using motivational interviewing for smokers hospitalised for an acute coronary syndrome: a multicentre before-after study with parallel group comparisons. <i>BMJ Open</i> , 2016 , 6, e011520	3	12
313	Effect of Bone Marrow-Derived Mononuclear Cell Treatment, Early or Late After Acute Myocardial Infarction: Twelve Months CMR and Long-Term Clinical Results. <i>Circulation Research</i> , 2016 , 119, 481-90	15.7	62
312	External validity of the "all-comers" design: insights from the BIOSCIENCE trial. <i>Clinical Research in Cardiology</i> , 2016 , 105, 744-54	6.1	10
311	Percutaneous Coronary Interventions for the Treatment of Stenoses in Small Coronary Arteries: A Network Meta-Analysis. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1324-34	5	44
310	Acute Gain in Minimal Lumen Area Following Implantation of Everolimus-Eluting ABSORB Biodegradable Vascular Scaffolds or Xience Metallic Stents: Intravascular Ultrasound Assessment From the ABSORB II Trial. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1216-1227	5	14
309	The Electrocardiogram After Transcatheter Aortic Valve Replacement Determines the Risk for Post-Procedural High-Degree AV Block and the Need for Telemetry Monitoring. <i>JACC:</i> Cardiovascular Interventions, 2016 , 9, 1269-1276	5	79
308	Effect of Diabetes Mellitus on Frequency of Adverse Events in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2016 , 118, 345-52	3	11
307	Regression of coronary atherosclerosis: Current evidence and future perspectives. <i>Trends in Cardiovascular Medicine</i> , 2016 , 26, 150-61	6.9	17
306	Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. <i>JACC:</i> Cardiovascular Interventions, 2016 , 9, 138-47	5	43
305	Temporal trends in the treatment and outcomes of elderly patients with acute coronary syndrome. <i>European Heart Journal</i> , 2016 , 37, 1304-11	9.5	65

(2016-2016)

304	Mechanisms of Very Late Drug-Eluting Stent Thrombosis Assessed by Optical Coherence Tomography. <i>Circulation</i> , 2016 , 133, 650-60	16.7	200
303	Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. <i>European Heart Journal</i> , 2016 , 37, 229-40	9.5	159
302	Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials. <i>JACC:</i> Cardiovascular Interventions, 2016 , 9, 28-38	5	24
301	Barriers to cardiovascular device innovation in Europe. European Heart Journal, 2016, 37, 140-4	9.5	5
300	Prognostic value of PCSK9 levels in patients with acute coronary syndromes. <i>European Heart Journal</i> , 2016 , 37, 546-53	9.5	89
299	Reply: Mechanisms of Late and Very Late Bioresorbable Vascular Scaffold Thrombosis: Is it Only About Flow?. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1260	15.1	1
298	Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial. <i>European Heart Journal</i> , 2016 , 37, 2029-36	9.5	99
297	Changes of coronary plaque composition correlate with C-reactive protein levels in patients with ST-elevation myocardial infarction following high-intensity statin therapy. <i>Atherosclerosis</i> , 2016 , 247, 154-60	3.1	16
296	Intracoronary imaging of coronary atherosclerosis: validation for diagnosis, prognosis and treatment. <i>European Heart Journal</i> , 2016 , 37, 524-35a-c	9.5	67
295	Developing drugs for use before, during and soon after percutaneous coronary intervention. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 803-18	4	9
294	Thrombectomy in Primary Angioplasty: Do the Latest Large Studies Address the Doubts About Its Usefulness? Response. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016 , 69, 231	0.7	
293	Trombectom en angioplastia primaria: ¿aclaran los Limos grandes estudios las dudas sobre su utilidad? Respuesta. <i>Revista Espanola De Cardiologia</i> , 2016 , 69, 231	1.5	
292	Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity: Patient-Level Pooled Analysis of 6081 Patients. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9, e003255	6	66
291	Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial. <i>American Heart Journal</i> , 2016 , 174, 95-102	4.9	37
290	Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2016 , 175, 56-65	4.9	42
289	Post-Procedural Troponin Elevation and Clinical Outcomes Following Transcatheter Aortic Valve Implantation. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	27
288	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9, e002995	6	9

286	Introducing a new EAPCI programme: the Valve for Life initiative. <i>EuroIntervention</i> , 2016 , 11, 977-9	3.1	9
285	Angiographic complexity of coronary artery disease according to SYNTAX score and clinical outcomes after revascularisation with newer-generation drug-eluting stents: a substudy of the BIOSCIENCE trial. <i>EuroIntervention</i> , 2016 , 12, e595-604	3.1	9
284	In vitro evaluation of implantation depth in valve-in-valve using different transcatheter heart valves. <i>EuroIntervention</i> , 2016 , 12, 909-17	3.1	37
283	External validity of a contemporaneous primary percutaneous coronary intervention trial in patients with acute ST-elevation myocardial infarction: insights from a single-centre investigation. <i>EuroIntervention</i> , 2016 , 12, 1135-1143	3.1	3
282	Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) versus the durable polymer everolimus-eluting metallic stent (XIENCE) in patients with acute ST-elevation myocardial infarction: rationale and design of the randomised	3.1	20
281	Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2016 , 12, 1239-1245	3.1	86
280	Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction. <i>EuroIntervention</i> , 2016 , 12, e1343-e1354	3.1	16
279	Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance. <i>Swiss Medical Weekly</i> , 2016 , 146, w14333	3.1	3
278	Left atrial appendage closure for prevention of cardioembolic events. <i>Swiss Medical Weekly</i> , 2016 , 146, w14298	3.1	1
277	Preprocedural High-Sensitivity Cardiac Troponin T and Clinical Outcomes in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9,	6	13
276	Predictors of Early (1-Week) Outcomes Following Left Atrial Appendage Closure With Amplatzer Devices. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1374-83	5	34
275	Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients With Coronary Artery Disease: A Meta-Analysis of Randomized Trials. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1419-34	5	253
274	First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the LEADERS all-comers randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2016 , 87, E248-60	2.7	33
273	Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials. <i>European Heart Journal</i> , 2016 , 37, 3503-351	2 9.5	202
272	The Biolimus Stent Family 2016 , 344-359		
271	The Biotronik Stent Family 2016, 360-367		
270	A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?. <i>Circulation</i> , 2016 , 134, 1881-1906	16.7	53
269	Health utility indexes in patients with acute coronary syndromes. <i>Open Heart</i> , 2016 , 3, e000419	3	9

268	Repositionable Versus Balloon-Expandable Devices for Transcatheter Aortic Valve Implantation in Patients With Aortic Stenosis. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	22
267	Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction: Insights From the 2-Year Follow-Up of the BIOSCIENCE Trial. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 981-3	5	5
266	Reply: Intraluminal Scaffold Dismantling: The Downside of Positive Remodeling?. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2704	15.1	
265	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 674-84	5	35
264	Prevalence and Impact of Atrial Fibrillation in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement: An Analysis From the SOURCE XT Prospective Multicenter Registry. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 937-46	5	99
263	Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. <i>European Heart Journal</i> , 2016 , 37, 1967-76	9.5	279
262	Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial. <i>Journal of the American Heart Association</i> , 2016 , 5, e003255	6	45
261	Pooled Analysis Comparing the Efficacy of Intracoronary Versus Intravenous Abciximab in Smokers Versus Nonsmokers Undergoing Primary Percutaneous Coronary Revascularization for Acute ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2016 , 118, 1798-1804	3	2
260	Impact of Renal Dysfunction on Results of Transcatheter Aortic Valve Replacement Outcomes in a Large Multicenter Cohort. <i>American Journal of Cardiology</i> , 2016 , 118, 1888-1896	3	28
259	Joint EACVI HIT/EAPCI young survey/ESC CoT survey: training and education for Moultimodality imaging in structural interventions Nthe rise of a new sub-specialty?. European Heart Journal Cardiovascular Imaging, 2016, 17, 1432-1433	4.1	4
258	Evolution of Cognitive Function After Transcatheter Aortic Valve Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9,	6	23
257	1-Year Outcomes With Intracoronary Abciximab in Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 727-38	15.1	5
256	Prognosis of Patients With Familial Hypercholesterolemia After Acute Coronary Syndromes. <i>Circulation</i> , 2016 , 134, 698-709	16.7	79
255	Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study. JACC: Cardiovascular Interventions, 2015, 8, 1064-1074	5	4
254	Circulating FABP4 is a prognostic biomarker in patients with acute coronary syndrome but not in asymptomatic individuals. <i>Arteriosclerosis, Thrombosis, and Vascular Biology,</i> 2015 , 35, 1872-9	9.4	29
253	Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8,	6	27
252	Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents.	3	26
251	Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. European Heart Journal, 2015, 36, 2608-20	9.5	145

250	Aspiration Thrombectomy for Treatment of ST-segment Elevation Myocardial Infarction: a Meta-analysis of 26 Randomized Trials in 11,943 Patients. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015 , 68, 746-52	0.7	4
249	Anatomic characteristics and clinical implications of angiographic coronary thrombus: insights from a patient-level pooled analysis of SYNTAX, RESOLUTE, and LEADERS Trials. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8,	6	6
248	Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8,	6	46
247	Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1113-21	27.4	66
246	Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8,	6	185
245	Silent myocardial infarction and stroke: findings of multimodality imaging. <i>European Heart Journal</i> , 2015 , 36, 949	9.5	1
244	Clinical outcomes and revascularization strategies in patients with low-flow, low-gradient severe aortic valve stenosis according to the assigned treatment modality. <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 704-17	5	31
243	Impact of local endothelial shear stress on neointima and plaque following stent implantation in patients with ST-elevation myocardial infarction: A subgroup-analysis of the COMFORTABLE AMI-IBIS 4 trial. <i>International Journal of Cardiology</i> , 2015 , 186, 178-85	3.2	22
242	European experience with the second-generation Edwards SAPIEN XT transcatheter heart valve in patients with severe aortic stenosis: 1-year outcomes from the SOURCE XT Registry. <i>JACC:</i> Cardiovascular Interventions, 2015 , 8, 657-69	5	83
241	Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8, e001441	6	137
240	Republished: Antiplatelet therapy for secondary prevention of coronary artery disease. <i>Postgraduate Medical Journal</i> , 2015 , 91, 284-90	2	1
239	Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2211-21	15.1	193
238	Validity of SYNTAX score II for risk stratification of percutaneous coronary interventions: A patient-level pooled analysis of 5,433 patients enrolled in contemporary coronary stent trials. <i>International Journal of Cardiology</i> , 2015 , 187, 111-5	3.2	22
237	Validation of the Valve Academic Research Consortium Bleeding Definition in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. <i>Journal of the American Heart Association</i> , 2015 , 4, e002135	6	19
236	Effect of Pulmonary Hypertension Hemodynamic Presentation on Clinical Outcomes in Patients With Severe Symptomatic Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Implantation: Insights From the New Proposed Pulmonary Hypertension Classification. <i>Circulation:</i>	6	63
235	Response To Letter Regarding Article, Effect of Pulmonary Hypertension Hemodynamic Presentation on Clinical Outcomes in Patients With Severe Symptomatic Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Implantation: Insights From the New Proposed Pulmonary	6	3
234	Very Late Scaffold Thrombosis: Intracoronary Imaging and Histopathological and Spectroscopic Findings. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1901-14	15.1	155
233	Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 1552-62	5	36

232	Effect of B-type natriuretic peptides on long-term outcomes after transcatheter aortic valve implantation. <i>American Journal of Cardiology</i> , 2015 , 116, 1560-5	3	34
231	Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. <i>Lancet, The</i> , 2015 , 386, 655-64	40	186
230	Stable coronary artery disease: revascularisation and invasive strategies. <i>Lancet, The</i> , 2015 , 386, 702-13	40	108
229	Trombectom por aspiracifi para el tratamiento del infarto agudo de miocardio con elevacifi del segmento ST: un metan lisis de 26 ensayos aleatorizados con 11.943 pacientes. <i>Revista Espanola De Cardiologia</i> , 2015 , 68, 746-752	1.5	12
228	Comparative Effectiveness and Safety of New-Generation Versus Early-Generation Drug-Eluting Stents According to Complexity of Coronary Artery Disease: A Patient-Level Pooled Analysis of 6,081 Patients. <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 1657-66	5	22
227	Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study. <i>European Heart Journal</i> , 2015 , 36, 490-500	9.5	115
226	Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis. <i>European Heart Journal</i> , 2015 , 36, 120-8	9.5	82
225	Long-term outcome of elderly patients with severe aortic stenosis as a function of treatment modality. <i>Heart</i> , 2015 , 101, 30-6	5.1	23
224	Response to Letter Regarding Article, "Prognostications of Fibrillations". <i>Stroke</i> , 2015 , 46, e191	6.7	
223	Age- and Gender-related Disparities in Primary Percutaneous Coronary Interventions for Acute ST-segment elevation Myocardial Infarction. <i>PLoS ONE</i> , 2015 , 10, e0137047	3.7	23
222	Technical Approach Determines Inflammatory Response after Surgical and Transcatheter Aortic Valve Replacement. <i>PLoS ONE</i> , 2015 , 10, e0143089	3.7	17
221	The association between in-stent neoatherosclerosis and native coronary artery disease progression: a long-term angiographic and optical coherence tomography cohort study. <i>European Heart Journal</i> , 2015 , 36, 2167-76	9.5	65
220	Clinical impact of gastrointestinal bleeding in patients undergoing percutaneous coronary interventions. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8,	6	58
219	The future of transcatheter mitral valve interventions: competitive or complementary role of repair vs. replacement?. <i>European Heart Journal</i> , 2015 , 36, 1651-9	9.5	133
218	Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2860-2868	15.1	88
217	Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8, e002230	6	95
216	Expanding Indications of Transcatheter Heart Valve Interventions. <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 1777-96	5	45
215	Procedural Results and Clinical Outcomes of Transcatheter Aortic Valve Implantation in Switzerland: An Observational Cohort Study of Sapien 3 Versus Sapien XT Transcatheter Heart Valves. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8,	6	54

214	Reply: could late enhancement and need for permanent pacemaker implantation in patients undergoing TAVR be explained by undiagnosed transthyretin cardiac amyloidosis?. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 313	15.1	
213	Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes. <i>European Journal of Internal Medicine</i> , 2015 , 26, 56-62	3.9	31
212	Stent thrombosis in early-generation drug-eluting stents versus newer-generation everolimus-eluting stent assorted by LVEF. <i>Heart</i> , 2015 , 101, 50-7	5.1	8
211	Biolimus-eluting stent with biodegradable polymer improves clinical outcomes in patients with acute myocardial infarction. <i>Heart</i> , 2015 , 101, 271-8	5.1	11
2 10	Impact of mitral regurgitation on clinical outcomes of patients with low-ejection fraction, low-gradient severe aortic stenosis undergoing transcatheter aortic valve implantation. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8, e001895	6	16
209	Reply: patent foramen ovale and paradoxical systemic embolism: can we determine high-risk characteristics by echocardiography?. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 223	15.1	
208	Can coronary computed tomography angiography replace invasive angiography? Coronary computed tomography angiography cannot replace invasive angiography. <i>Circulation</i> , 2015 , 131, 418-25; discussion 426	16.7	26
207	Time for science to catch up with clinical practice?. <i>Journal of Thoracic Disease</i> , 2015 , 7, E603-6	2.6	2
206	Impact of B-type natriuretic peptide on short-term clinical outcomes following transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2015 , 10, e1-8	3.1	22
205	Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials. <i>EuroIntervention</i> , 2015 , 10, 1425-31	3.1	14
204	Clinical outcome of patients with stable ischaemic heart disease as compared to those with acute coronary syndromes after percutaneous coronary intervention. <i>EuroIntervention</i> , 2015 , 11, 171-9	3.1	9
203	2014 ESC/EACTS guidelines on myocardial revascularization. <i>EuroIntervention</i> , 2015 , 10, 1024-94	3.1	195
202	Thrombus formation in the left ventricle after large myocardial infarction lassessment with cardiac magnetic resonance imaging. <i>Swiss Medical Weekly</i> , 2015 , 145, w14122	3.1	8
201	Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INFARCTION) and COMFORTABLE-AMI	5	75
200	Anatomical eligibility of the renal vasculature for catheter-based renal denervation in hypertensive patients. <i>JACC: Cardiovascular Interventions</i> , 2014 , 7, 187-192	5	16
199	Coronary stents: novel developments. <i>Heart</i> , 2014 , 100, 1051-61	5.1	55
198	Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. <i>Lancet, The</i> , 2014 , 384, 2111-22	40	184
197	Local and general anaesthesia do not influence outcome of transfemoral aortic valve implantation. <i>International Journal of Cardiology</i> , 2014 , 177, 448-54	3.2	56

196	Short versus long duration of DAPT after DES implantation: a meta-analysis. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 953-4	15.1	24
195	Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta-analysis. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 129-40	15.1	390
194	Paradoxical embolism. Journal of the American College of Cardiology, 2014, 64, 403-15	15.1	121
193	2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European	9.5	3467
192	Fluoroscopic anatomy of left-sided heart structures for transcatheter interventions: insight from multislice computed tomography. <i>JACC: Cardiovascular Interventions</i> , 2014 , 7, 947-57	5	39
191	Antiplatelet therapy for secondary prevention of coronary artery disease. <i>Heart</i> , 2014 , 100, 1750-6	5.1	28
190	Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. <i>European Heart Journal</i> , 2014 , 35, 1949-56	9.5	95
189	Open issues in transcatheter aortic valve implantation. Part 2: procedural issues and outcomes after transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2014 , 35, 2639-54	9.5	76
188	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis,	9.5	413
187	European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Preinterventional screening of the TAVI patient: how to choose the suitable patient and the best procedure: Clinical Research in Cardiology, 2014, 103, 259-74 o. European Heart Journal, 2014, 35, 3155-1	₇ 6.1	30
186	Biolimus-eluting stents with biodegradable polymer versus bare-metal stents in acute myocardial infarction: two-year clinical results of the COMFORTABLE AMI trial. <i>Circulation: Cardiovascular Interventions</i> , 2014 , 7, 355-64	6	50
185	Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. <i>BMJ, The</i> , 2014 , 348, g3859	5.9	210
184	4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous	15.1	129
183	Predicting 3-year mortality after percutaneous coronary intervention: updated logistic clinical SYNTAX score based on patient-level data from 7 contemporary stent trials. <i>JACC: Cardiovascular Interventions</i> , 2014 , 7, 464-70	5	37
182	Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial. <i>American Heart Journal</i> , 2014 , 168, 256-61	4.9	14
181	Lack of blood pressure-lowering effect of renal denervation in a drug-nalle patient with pronounced arterial stiffening. <i>American Journal of Medicine</i> , 2014 , 127, e3-4	2.4	6
180	The MI SYNTAX score for risk stratification in patients undergoing primary percutaneous coronary intervention for treatment of acute myocardial infarction: a substudy of the COMFORTABLE AMI trial. <i>International Journal of Cardiology</i> , 2014 , 175, 314-22	3.2	19
179	68 Predicting 3-Year Mortality After PCI: Revised Clinical Syntax Model Based on Patient Level Data from 7 Contemporary Stent Trials. <i>Heart</i> , 2014 , 100, A38.2-A39	5.1	

178	Feasibility and outcomes of combined transcatheter aortic valve replacement with other structural heart interventions in a single session: a matched cohort study. <i>Open Heart</i> , 2014 , 1, e000014	3	9
177	Neoatherosclerosis as reason for stent failures beyond 5 years after drug-eluting stent implantation. <i>European Heart Journal</i> , 2014 , 35, 1980	9.5	6
176	Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials. <i>Heart</i> , 2014 , 100, 1158-64	5.1	144
175	Coronary artery disease severity and aortic stenosis: clinical outcomes according to SYNTAX score in patients undergoing transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2014 , 35, 2530-	40 5	96
174	Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the	5	97
173	2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European	3	588
172	Treatment of aortic stenosis with a self-expanding transcatheter valve: the International Multi-centre ADVANCE Study. <i>European Heart Journal</i> , 2014 , 35, 2672-84	9.5	171
171	Stents liberadores de paclitaxel en el infarto agudo de miocardio con elevacili del segmento ST. <i>Revista Espanola De Cardiologia</i> , 2014 , 67, 974-979	1.5	1
170	Transcatheter aortic valve replacement in bicuspid aortic valve disease. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2330-9	15.1	228
169	Coronary evaginations are associated with positive vessel remodelling and are nearly absent following implantation of newer-generation drug-eluting stents: an optical coherence tomography and intravascular ultrasound study. <i>European Heart Journal</i> , 2014 , 35, 795-807	9.5	51
168	Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 162-70	27.4	568
167	Open issues in transcatheter aortic valve implantation. Part 1: patient selection and treatment strategy for transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2014 , 35, 2627-38	9.5	71
166	Stent performance: never too late to sort it out. Lancet, The, 2014, 383, 2024-2026	40	2
165	Differential healing response attributed to culprit lesions of patients with acute coronary syndromes and stable coronary artery after implantation of drug-eluting stents: an optical coherence tomography study. <i>International Journal of Cardiology</i> , 2014 , 173, 259-67	3.2	38
164	The impact of renal impairment on long-term safety and effectiveness of drug-eluting stents. <i>PLoS ONE</i> , 2014 , 9, e106450	3.7	8
163	The self-expanding Symetis Acurate does not increase cerebral microembolic load when compared to the balloon-expandable Edwards Sapien prosthesis: a transcranial Doppler study in patients undergoing transapical aortic valve implantation. <i>PLoS ONE</i> , 2014 , 9, e108191	3.7	6
162	Additive effect of anemia and renal impairment on long-term outcome after percutaneous coronary intervention. <i>PLoS ONE</i> , 2014 , 9, e114846	3.7	9
161	Short-term clinical outcomes among patients undergoing transcatheter aortic valve implantation in Switzerland: the Swiss TAVI registry. <i>EuroIntervention</i> , 2014 , 10, 982-9	3.1	48

Management of ST-elevation myocardial infarction according to European and American guidelines. <i>EuroIntervention</i> , 2014 , 10 Suppl T, T23-31	3.1	23
Coronary artery disease in patients undergoing TAVI: why, what, when and how to treat. <i>EuroIntervention</i> , 2014 , 10 Suppl U, U69-75	3.1	17
Assessment of low-flow, low-gradient, severe aortic stenosis: an invasive evaluation is required for decision making. <i>EuroIntervention</i> , 2014 , 10 Suppl U, U61-8	3.1	5
Long-term comparison of everolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for percutaneous coronary intervention of saphenous vein grafts. <i>EuroIntervention</i> , 2014 , 9, 1432-40	3.1	16
Future treatment strategies in ST-segment elevation myocardial infarction. <i>Lancet, The</i> , 2013 , 382, 644	-5470	48
Transcatheter aortic valve implantation and bleeding: incidence, predictors and prognosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 35, 456-62	5.1	51
Prediction of 1-year mortality in patients with acute coronary syndromes undergoing percutaneous coronary intervention: validation of the logistic clinical SYNTAX (Synergy Between Percutaneous Coronary Interventions With Taxus and Cardiac Surgery) score. <i>JACC: Cardiovascular Interventions</i> ,	5	42
Clinical endpoint adjudication in a contemporary all-comers coronary stent investigation: methodology and external validation. <i>Contemporary Clinical Trials</i> , 2013 , 34, 53-9	2.3	8
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013 , 145, 6-23	1.5	647
Patent foramen ovale screening by ear oximetry in divers. <i>American Journal of Cardiology</i> , 2013 , 111, 286-90	3	14
Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. <i>Lancet, The</i> , 2013 , 382, 1879-88	40	102
Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials. <i>International Journal of Cardiology</i> , 2013 , 168, 5162-6	3.2	28
Transcatheter aortic valve replacement in Europe: adoption trends and factors influencing device utilization. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 210-219	15.1	159
Tissue coverage and neointimal hyperplasia in overlap versus nonoverlap segments of drug-eluting stents 9 to 13 months after implantation: in vivo assessment with optical coherence tomography. <i>American Heart Journal</i> , 2013 , 166, 83-94	4.9	20
Future perspectives in transcatheter aortic valve implantation. <i>International Journal of Cardiology</i> , 2013 , 168, 11-8	3.2	17
Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus	5	254
Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis. <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, 905-13	5	18
Aortic root dimensions among patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, 72-83	5	79
	Coronary artery disease in patients undergoing TAVI: why, what, when and how to treat. EuroIntervention, 2014, 10 Suppl U, U69-75 Assessment of low-flow, low-gradient, severe aortic stenosis: an invasive evaluation is required for decision making. EuroIntervention, 2014, 10 Suppl U, U61-8 Long-term comparison of everolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for percutaneous coronary intervention of saphenous vein grafts. EuroIntervention, 2014, 9, 1432-40 Future treatment strategies in ST-segment elevation myocardial infarction. Lancet, The, 2013, 382, 644 Transcatheter aortic valve implantation and bleeding: incidence, predictors and prognosis. Journal of Thrombosis and Thrombolysis, 2013, 35, 456-62 Prediction of 1-year mortality in patients with acute coronary syndromes undergoing percutaneous coronary interventions with Taxus and Cardiac Surgery) score. JACC: Cardiovascular Interventions, 2013	Coronary artery disease in patients undergoing TAVI: why, what, when and how to treat. EuroIntervention, 2014, 10 Suppl U, U59-75 Assessment of low-flow, low-gradient, severe aortic stenosis: an invasive evaluation is required for decision making. EuroIntervention, 2014, 10 Suppl U, U61-8 Long-term comparison of everolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for percutaneous coronary intervention of saphenous vein grafts. EuroIntervention, 2014, 9, 1432-40 Future treatment strategies in ST-segment elevation myocardial infarction. Lancet, The, 2013, 382, 644-550 Transcatheter aortic valve implantation and bleeding: incidence, predictors and prognosis. Journal of Thrombosis and Thrombolysis, 2013, 35, 456-62 Prediction of 1-year mortality in patients with acute coronary syndromes undergoing percutaneous coronary Interventions wildiation of the logistic clinical SYNTAX (Synergy Between Percutaneous Coronary Interventions With Taxus and Cardiac Surgery) score. JACC: Cardiovascular Interventions, Clinical endpoint adjudication in a contemporary all-comers coronary stent investigation: methodology and external validation. Contemporary Clinical Trials, 2013, 34, 53-9 Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Journal of Thoracic and Cardiovascular Surgery, 2013, 145, 6-23 Patent Foramen ovale screening by ear oximetry in divers. American Journal of Cardiology, 2013, 111, 286-90 Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. Lancet, The, 2013, 382, 1879-88 Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials. International Journal of Cardiology, 2013, 168, 5162-6 Transcatheter aortic valve replacement in Europe: adoption trends and factors influencing device utilization. Journal of the American

142	Percutaneous closure of patent foramen ovale in cryptogenic embolism. <i>New England Journal of Medicine</i> , 2013 , 368, 1083-91	59.2	617
141	Predictors of functional decline in elderly patients undergoing transcatheter aortic valve implantation (TAVI). <i>European Heart Journal</i> , 2013 , 34, 684-92	9.5	211
140	Clinical outcomes of patients with low-flow, low-gradient, severe aortic stenosis and either preserved or reduced ejection fraction undergoing transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2013 , 34, 3437-50	9.5	83
139	Clinical outcomes of patients with estimated low or intermediate surgical risk undergoing transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2013 , 34, 1894-905	9.5	113
138	Coronary revascularisation in patients with diabetes: a chance to be better. <i>Evidence-Based Medicine</i> , 2013 , 18, e59		
137	Atrial fibrillation and aortic stenosis: impact on clinical outcomes among patients undergoing transcatheter aortic valve implantation. <i>Circulation: Cardiovascular Interventions</i> , 2013 , 6, 77-84	6	77
136	Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program. <i>Heart</i> , 2013 , 99, 626-33	5.1	26
135	The 2011-12 pilot European Sentinel Registry of Transcatheter Aortic Valve Implantation: in-hospital results in 4,571 patients. <i>EuroIntervention</i> , 2013 , 8, 1362-71	3.1	142
134	Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with drug-eluting stents. <i>EuroIntervention</i> , 2013 , 8, 1061-71	3.1	33
133	Severe aortic stenosis and coronary artery disease. <i>EuroIntervention</i> , 2013 , 9 Suppl, S63-8	3.1	29
132	Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque?. <i>Atherosclerosis</i> , 2012 , 221, 106-12	3.1	96
131	Very Late Stent Thrombosis With Newer Drug-Eluting Stents: No Longer an Issue?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012 , 65, 595-598	0.7	
130	Different cardiac biomarkers to detect peri-procedural myocardial infarction in contemporary coronary stent trials: impact on outcome reporting. <i>Heart</i> , 2012 , 98, 1424-30	5.1	22
129	Guidelines on the management of valvular heart disease (version 2012). <i>European Heart Journal</i> , 2012 , 33, 2451-96	9.5	2866
128	Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. <i>Circulation</i> , 2012 , 125, 1110-21	16.7	280
127	Impact of incomplete stent apposition on long-term clinical outcome after drug-eluting stent implantation. <i>European Heart Journal</i> , 2012 , 33, 1334-43	9.5	76
126	Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Journal of Cardio-thoracic	3	1002
125	Surgery, 2012 , 42, S1-44 Long-term clinical and angiographic outcomes of diabetic patients after revascularization with early generation drug-eluting stents. <i>American Heart Journal</i> , 2012 , 163, 876-886.e2	4.9	20

124	Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. <i>European Heart Journal</i> , 2012 , 33, 3098-104	9.5	113
123	Impact of permanent pacemaker implantation on clinical outcome among patients undergoing transcatheter aortic valve implantation. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 493-50	1 ^{15.1}	165
122	Third universal definition of myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 1581-98	15.1	2143
121	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 1438-54	15.1	1306
120	Long-term comparison of everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes. <i>JACC: Cardiovascular Interventions</i> , 2012 , 5, 145-54	5	15
119	Impact of sex on clinical and angiographic outcomes among patients undergoing revascularization with drug-eluting stents. <i>JACC: Cardiovascular Interventions</i> , 2012 , 5, 301-10	5	57
118	Percutaneous management of vascular complications in patients undergoing transcatheter aortic valve implantation. <i>JACC: Cardiovascular Interventions</i> , 2012 , 5, 515-524	5	62
117	Evaluation of multidimensional geriatric assessment as a predictor of mortality and cardiovascular events after transcatheter aortic valve implantation. <i>JACC: Cardiovascular Interventions</i> , 2012 , 5, 489-49	र्ह	222
116	Long-term vascular healing in response to sirolimus- and paclitaxel-eluting stents: an optical coherence tomography study. <i>JACC: Cardiovascular Interventions</i> , 2012 , 5, 946-57	5	48
115	Coronary stent choice in patients with acute myocardial infarction. <i>Current Cardiology Reports</i> , 2012 , 14, 477-85	4.2	2
114	Transcranial Doppler-detected cerebral embolic load during transcatheter aortic valve implantation. <i>European Journal of Cardio-thoracic Surgery</i> , 2012 , 41, 778-83; discussion 783-4	3	87
113	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. <i>European Heart Journal</i> , 2012 , 33, 2403-18	9.5	706
112	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). <i>European Journal of Cardio-thoracic Surgery</i> , 2012 , 42, S45-60	3	554
111	Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 777-87	27.4	225
110	Transcatheter aortic valve implantation: prevention and management of complications. <i>Heart</i> , 2012 , 98 Suppl 4, iv52-64	5.1	18
109	Long-term propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism. <i>Circulation</i> , 2012 , 125, 803-12	16.7	129
108	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012 , 33, 2569-619	9.5	3978
107	Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2012 , 33, 977-87	9.5	114

106	Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. <i>European Heart Journal</i> ,	9.5	296
105	2012 , 33, 1214-22 Vascular tissue reaction to acute malapposition in human coronary arteries: sequential assessment with optical coherence tomography. <i>Circulation: Cardiovascular Interventions</i> , 2012 , 5, 20-9, S1-8	6	86
104	The impact of anemia on long-term clinical outcome in patients undergoing revascularization with the unrestricted use of drug-eluting stents. <i>Circulation: Cardiovascular Interventions</i> , 2012 , 5, 202-10	6	50
103	Transcatheter aortic valve implantation: the procedure. <i>Heart</i> , 2012 , 98 Suppl 4, iv44-51	5.1	33
102	Comparison of biolimus eluted from an erodible stent coating with bare metal stents in acute ST-elevation myocardial infarction (COMFORTABLE AMI trial): rationale and design. <i>EuroIntervention</i> , 2012 , 7, 1435-43	3.1	25
101	Cerebrovascular accidents complicating transcatheter aortic valve implantation: frequency, timing and impact on outcomes. <i>EuroIntervention</i> , 2012 , 8, 62-70	3.1	86
100	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. <i>EuroIntervention</i> , 2012 , 8, 782-95	3.1	149
99	Transcatheter aortic valve implantation and cerebrovascular accidents. <i>EuroIntervention</i> , 2012 , 8 Suppl Q, Q60-9	3.1	15
98	Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 253-69	15.1	662
97	Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 2143-51	15.1	78
96	The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting	15.1	84
95	stent for percutaneous coronary intervention). <i>Journal of the American College of Cardiology</i> , 2011 , Clinical outcomes of patients with severe aortic stenosis at increased surgical risk according to treatment modality. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 2151-62	15.1	121
94	2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice. <i>JACC: Cardiovascular Interventions</i> , 2011 , 4, 887-95	5	29
93	Randomized clinical trial comparing percutaneous closure of patent foramen ovale (PFO) using the Amplatzer PFO Occluder with medical treatment in patients with cryptogenic embolism (PC-Trial): rationale and design. <i>Trials</i> , 2011 , 12, 56	2.8	13
92	Clinical outcome and predictors for adverse events after transcatheter aortic valve implantation with the use of different devices and access routes. <i>American Heart Journal</i> , 2011 , 161, 1114-24	4.9	103
91	Long-term tissue coverage of a biodegradable polylactide polymer-coated biolimus-eluting stent: comparative sequential assessment with optical coherence tomography until complete resorption of the polymer. <i>American Heart Journal</i> , 2011 , 162, 922-31	4.9	40
90	Acute coronary syndromes in young patients: presentation, treatment and outcome. <i>International Journal of Cardiology</i> , 2011 , 148, 300-4	3.2	101
89	Current status of drug-eluting stents. Cardiovascular Therapeutics, 2011, 29, 176-89	3.3	37

88	Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. <i>Lancet, The</i> , 2011 , 377, 1241-7	40	192
87	Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. <i>Lancet, The</i> , 2011 , 378, 1940-8	40	283
86	Clinical outcome of high-risk patients with severe aortic stenosis and reduced left ventricular ejection fraction undergoing medical treatment or TAVI. <i>PLoS ONE</i> , 2011 , 6, e27556	3.7	39
85	Impact of body mass index on the five-year outcome of patients having percutaneous coronary interventions with drug-eluting stents. <i>American Journal of Cardiology</i> , 2011 , 108, 195-201	3	35
84	Sirolimus versus paclitaxel coronary stents in clinical practice. <i>Catheterization and Cardiovascular Interventions</i> , 2011 , 77, 5-12	2.7	8
83	Clinical use of temporary percutaneous left ventricular assist devices. <i>Catheterization and Cardiovascular Interventions</i> , 2011 , 78, 304-13	2.7	14
82	The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial. <i>JACC:</i> Cardiovascular Interventions, 2011 , 4, 432-41	5	83
81	Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial. <i>JACC: Cardiovascular Interventions</i> , 2011 , 4, 672-82	5	18
80	A patient-level pooled analysis assessing the impact of the SYNTAX (synergy between percutaneous coronary intervention with taxus and cardiac surgery) score on 1-year clinical outcomes in 6,508 patients enrolled in contemporary coronary stent trials. <i>JACC: Cardiovascular</i>	5	63
79	Interventions, 2011, 4, 645-53 Delayed coverage in malapposed and side-branch struts with respect to well-apposed struts in drug-eluting stents: in vivo assessment with optical coherence tomography. <i>Circulation</i> , 2011, 124, 612-	216.7	104
78	Value of age, creatinine, and ejection fraction (ACEF score) in assessing risk in patients undergoing percutaneous coronary interventions in the Mall-ComersNLEADERS trial. <i>Circulation: Cardiovascular Interventions</i> , 2011 , 4, 47-56	6	85
77	Patent foramen ovale may be causal for the first stroke but unrelated to subsequent ischemic events. <i>Stroke</i> , 2011 , 42, 2891-5	6.7	23
76	Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial. <i>European Heart Journal</i> , 2011 , 32, 2454-63	9.5	107
75	SYNTAX score and Clinical SYNTAX score as predictors of very long-term clinical outcomes in patients undergoing percutaneous coronary interventions: a substudy of SIRolimus-eluting stent compared with pacliTAXel-eluting stent for coronary revascularization (SIRTAX) trial. <i>European</i>	9.5	109
74	Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. <i>Circulation</i> , 2011 , 123, 2819-28, 6 p following 2828	16.7	143
73	The outcome of bifurcation lesion stenting using a biolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer. <i>EuroIntervention</i> , 2011 , 6, 928-3	5 ^{3.1}	16
72	Impact of coronary artery disease and percutaneous coronary intervention on outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2011 , 7, 541-8	3.1	128
71	Implantation of the biodegradable polymer biolimus-eluting stent in patients with high SYNTAX score is associated with decreased cardiac mortality compared to a permanent polymer sirolimus-eluting stent: two year follow-up results from the "all-comers" LEADERS trial.	3.1	20

70	The three year follow-up of the randomised "all-comers" trial of a biodegradable polymer biolimus-eluting stent (LEADERS). <i>EuroIntervention</i> , 2011 , 7, 789-95	3.1	34
69	Improvement of migraine headaches after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism. <i>Heart</i> , 2010 , 96, 967-73	5.1	59
68	Controversies in cardiovascular medicine: Chronic stable coronary artery disease: drugs vs. revascularization. <i>European Heart Journal</i> , 2010 , 31, 530-41	9.5	60
67	An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. <i>European Heart Journal</i> , 2010 , 31, 165-76	9.5	210
66	Impact of stent overlap on angiographic and long-term clinical outcome in patients undergoing drug-eluting stent implantation. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 1178-1188	15.1	117
65	Value of the SYNTAX score for risk assessment in the all-comers population of the randomized multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 272-7	15.1	171
64	Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. <i>New England Journal of Medicine</i> , 2010 , 363, 136-46	59.2	519
63	Relationship between the logistic EuroSCORE and the Society of Thoracic Surgeons Predicted Risk of Mortality score in patients implanted with the CoreValve ReValving systema Bern-Rotterdam Study. <i>American Heart Journal</i> , 2010 , 159, 323-9	4.9	134
62	Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation. <i>American Heart Journal</i> , 2010 , 159, 891-898.e1	4.9	35
61	Guidelines on myocardial revascularization. European Heart Journal, 2010 , 31, 2501-55	9.5	2070
61	Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2010 , 31, 2501-55 Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. <i>European Heart Journal</i> , 2010 , 31, 943-57	9·5 9·5	2070 426
	Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the		
60	Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. <i>European Heart Journal</i> , 2010 , 31, 943-57 The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with Biolimus- and Sirolimus-eluting stents (from the LEADERS Trial).	9.5	426
60 59	Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. <i>European Heart Journal</i> , 2010 , 31, 943-57 The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with Biolimus- and Sirolimus-eluting stents (from the LEADERS Trial). <i>American Journal of Cardiology</i> , 2010 , 105, 475-9 Incidence and predictors of atrioventricular conduction impairment after transcatheter aortic valve	9.5	426
605958	Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. <i>European Heart Journal</i> , 2010 , 31, 943-57 The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with Biolimus- and Sirolimus-eluting stents (from the LEADERS Trial). <i>American Journal of Cardiology</i> , 2010 , 105, 475-9 Incidence and predictors of atrioventricular conduction impairment after transcatheter aortic valve implantation. <i>American Journal of Cardiology</i> , 2010 , 106, 1473-80 Impact of arterial injury on neointimal hyperplasia after implantation of drug-eluting stents in	9.5	426 44 135
60595857	Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. <i>European Heart Journal</i> , 2010 , 31, 943-57 The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with Biolimus- and Sirolimus-eluting stents (from the LEADERS Trial). <i>American Journal of Cardiology</i> , 2010 , 105, 475-9 Incidence and predictors of atrioventricular conduction impairment after transcatheter aortic valve implantation. <i>American Journal of Cardiology</i> , 2010 , 106, 1473-80 Impact of arterial injury on neointimal hyperplasia after implantation of drug-eluting stents in coronary arteries: an intravascular ultrasound study. <i>EuroIntervention</i> , 2010 , 6, 467-74 Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. <i>EuroIntervention</i> , 2010 ,	9.533.1	426 44 135 5
6059585756	Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. <i>European Heart Journal</i> , 2010 , 31, 943-57 The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with Biolimus- and Sirolimus-eluting stents (from the LEADERS Trial). <i>American Journal of Cardiology</i> , 2010 , 105, 475-9 Incidence and predictors of atrioventricular conduction impairment after transcatheter aortic valve implantation. <i>American Journal of Cardiology</i> , 2010 , 106, 1473-80 Impact of arterial injury on neointimal hyperplasia after implantation of drug-eluting stents in coronary arteries: an intravascular ultrasound study. <i>EuroIntervention</i> , 2010 , 6, 467-74 Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. <i>EuroIntervention</i> , 2010 , 5, 871-4	9.5 3 3.1 3.1	426 44 135 5

(2008-2009)

52	Head-to-Head and Extrapolated Comparisons of Different Drug-Eluting Stents: Differences in Late Loss, Restenosis, and Clinical Outcomes. <i>Journal of Interventional Cardiology</i> , 2009 , 22, S48-S63	1.8	O
51	Late results after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism using the amplatzer PFO occluder without intraprocedural echocardiography: effect of device size. <i>JACC: Cardiovascular Interventions</i> , 2009 , 2, 116-23	5	54
50	Impact of vessel size on angiographic and clinical outcomes of revascularization with biolimus-eluting stent with biodegradable polymer and sirolimus-eluting stent with durable polymer the LEADERS trial substudy. <i>JACC: Cardiovascular Interventions</i> , 2009 , 2, 861-70	5	38
49	Surgical versus percutaneous revascularization of coronary artery disease in diabetic patients. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009 , 23, 317-34	6.5	3
48	Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. <i>Circulation</i> , 2009 , 120, 391-9	16.7	388
47	Vascular restoration therapy: what should the clinical and angiographic measures for success be?. <i>EuroIntervention</i> , 2009 , 5 Suppl F, F49-53	3.1	7
46	Biolimus-eluting biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions: results from the LEADERS multicentre trial substudy. <i>EuroIntervention</i> , 2009 , 5, 310-7	3.1	12
45	Age-related differences in the use of guideline-recommended medical and interventional therapies for acute coronary syndromes: a cohort study. <i>Journal of the American Geriatrics Society</i> , 2008 , 56, 510-	6 ^{5.6}	86
44	Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 1134-	40 ^{5.1}	404
43	Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. <i>Lancet, The</i> , 2008 , 372, 1163-73	40	531
42	Safety of drug-eluting stents. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 316-28		17
41	Atrial fibrillation following device closure of patent foramen ovale. <i>Cardiology</i> , 2008 , 111, 47-50	1.6	31
40	Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. <i>BMJ, The</i> , 2008 , 337, a1331	5.9	209
39	Is closure recommended for patent foramen ovale and cryptogenic stroke? Patent foramen ovale and cryptogenic stroke: to close or not to close? Closure: what else!. <i>Circulation</i> , 2008 , 118, 1989-98	16.7	50
38	Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients. <i>European Heart Journal</i> , 2008 , 29, 718-25	9.5	58
37	Percutaneous closure of patent foramen ovale, atrial septal defects and the left atrial appendage 2008 , 449-468		
36	Acute coronary syndromes: management and secondary prevention. <i>Herz</i> , 2008 , 33, 25-37	2.6	6
35	Percutaneous ventricular assist devices for cardiogenic shock. <i>Current Heart Failure Reports</i> , 2008 , 5, 163-9	2.8	12

34	Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. <i>EuroIntervention</i> , 2008 , 4, 242-9	3.1	509
33	Safety and feasibility of percutaneous closure of patent foramen ovale without intra-procedural echocardiography in 825 patients. <i>Swiss Medical Weekly</i> , 2008 , 138, 567-72	3.1	23
32	Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. <i>Circulation</i> , 2007 , 115, 2426-34	16.7	662
31	Coronary collateral function long after drug-eluting stent implantation. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 15-20	15.1	59
30	Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1123-31	15.1	65
29	A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1373-8	0 ^{15.1}	253
28	Clinical relevance of coronary angiography at the time of percutaneous closure of a patent foramen ovale. <i>Catheterization and Cardiovascular Interventions</i> , 2007 , 70, 641-5	2.7	7
27	Late coronary stent thrombosis. <i>Circulation</i> , 2007 , 116, 1952-65	16.7	186
26	Percutaneous left ventricular assist devices for treatment of patients with cardiogenic shock. <i>Current Opinion in Critical Care</i> , 2007 , 13, 521-7	3.5	43
25	Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. <i>International Journal of Cardiology</i> , 2007 , 120, 212-20	3.2	88
24	Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. <i>Lancet, The</i> , 2007 , 369, 667-78	40	1634
23	Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. <i>Lancet, The</i> , 2007 , 370, 937-48	40	1141
22	Clinical end points in coronary stent trials: a case for standardized definitions. <i>Circulation</i> , 2007 , 115, 2344-51	16.7	4380
21	Sirolimus-eluting coronary stents in small vessels. <i>American Heart Journal</i> , 2006 , 151, 1019.e1-7	4.9	25
20	Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. <i>Circulation</i> , 2005 , 111, 2617-22	16.7	119
19	Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. <i>New England Journal of Medicine</i> , 2005 , 353, 653-62	59.2	480
18	Transcatheter treatment of atrial septal aneurysm associated with patent foramen ovale for prevention of recurrent paradoxical embolism in high-risk patients. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 377-80	15.1	100
17	Stent thrombosis is associated with an impaired response to antiplatelet therapy. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 1748-52	15.1	196

LIST OF PUBLICATIONS

16	Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 231-6	15.1	311
15	Percutaneous Closure of Patent Foramen Ovale with the Amplatzer PFO Occluder 2005 , 143-160		1
14	Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. <i>European Heart Journal</i> , 2005 , 26, 1180-7	9.5	153
13	Deleterious effect of coronary brachytherapy on vasomotor response to exercise. <i>Circulation</i> , 2004 , 110, 135-40	16.7	20
12	Evaluation and treatment of abnormalities of the interatrial septum. <i>Catheterization and Cardiovascular Interventions</i> , 2004 , 63, 94-103	2.7	8
11	Implantation of a second closure device in patients with residual shunt after percutaneous closure of patent foramen ovale. <i>Catheterization and Cardiovascular Interventions</i> , 2004 , 63, 490-5	2.7	29
10	Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 750-8	15.1	248
9	Sirolimus eluting stent: a new era in interventional cardiology?. <i>Current Pharmaceutical Design</i> , 2003 , 9, 1077-94	3.3	18
8	Effect of endurance training on coronary artery size and function in healthy men: an invasive followup study. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002 , 282, H2216-23	5.2	45
7	First Clinical Results With a New Mechanical Connector for Distal Coronary Artery Anastomoses in CABG. <i>Circulation</i> , 2002 , 106,	16.7	1
7 6		16.7	21
	CABG. Circulation, 2002, 106, Percutaneous closure of patent foramen ovale in symptomatic patients. Journal of Interventional		21
6	CABG. Circulation, 2002, 106, Percutaneous closure of patent foramen ovale in symptomatic patients. Journal of Interventional Cardiology, 2001, 14, 203-9 Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation,	1.8	21
6 5	CABG. Circulation, 2002, 106, Percutaneous closure of patent foramen ovale in symptomatic patients. Journal of Interventional Cardiology, 2001, 14, 203-9 Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation, 2001, 104, 2012-7 Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia. Circulation, 2001,	1.8	21
654	Percutaneous closure of patent foramen ovale in symptomatic patients. <i>Journal of Interventional Cardiology</i> , 2001 , 14, 203-9 Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. <i>Circulation</i> , 2001 , 104, 2012-7 Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia. <i>Circulation</i> , 2001 , 104, 928-33 Mechanical compression of coronary artery stents: potential hazard for patients undergoing	1.8 16.7 16.7	21 277 136